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Abstract 
The World Health Organization estimates almost 3.2 billion people remain at risk of malaria with 
200 million new cases  each year 1. Approximately 600,000 people die each year from malaria, 
most as a result of infection with the protozoan parasite Plasmodium falciparum. Almost 75% of 
those that die are under the age of five 2,3. While malaria is a preventable and treatable mosquito 
borne illness and antimalarial drugs do exist, they are becoming less effective and most do not 
effectively block transmission. This is compounded by the fact that resistance of the parasite to 
antimalarial drugs, including artemisinins, and resistance of the mosquito vector to insecticides is 
increasing 1, 4, 5.  A singular approach will not suffice to identify inhibitors that block the 
transmission of this pathogen 6. In this project two potential targets are evaluated. Approach one 
targets Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP), the sole aspartyl 
protease expressed in the parasite, and hence represents a unique opportunity for therapeutic 
intervention7,8.  In addition, its amino acid homology with that of human AAPs is not substantial 
providing an opportunity to find parasite specific inhibitors9. The second approach targets 
transmission which involves uptake of mature gametocytes by the mosquito vector prior to 
development into a fully functioning transmissible form. Hence this is another attractive target 
10,11. Key variables are not only reagent acquisition (of enzyme and gametocytes) but, also to 
determine the druggability of the aforementioned targets 12. The Malaria Biology Laboratory 
(Gardiner and Trenholme) at QIMR Berghofer Medical Research Institute has established current 
in vitro technologies for recombinant PfM18AAP (rPfM18AAP) production and gametocyte 
culture, thereby paving the path to assay development, implementation and High Throughput 
Screening (HTS) 13-14.  The Scripps Research Institutes Molecular Screening Center affords the 
unique and powerful capability to couple these two targets with ultra-high throughput screening 
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capability15. Both targets have successfully completed HTS. The AAP target has resulted in a 
published molecular probe, while the gametocyte target is undergoing refinement of the initial hits 
to bonafied leads 9.   
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Main Text of the Thesis 
 
Chapter 1-Introduction and Literature Review 
Introduction: 
According to the World Health Organization (WHO) up to 200 million people per year become 
infected with malaria resulting in an estimated 0.6 million fatalities. The young are primarily at 
risk with the majority of deaths from malaria occurring in those that are under five years of age  
and strikingly, in parts of Africa results in up to 15% of deaths for the same age range. Malaria 
accounts for roughly 1 out of 100 deaths worldwide even though it is typically only found in areas 
of tropical climate. While the rate of malaria transmission has leveled off and even slightly 
declined in the past few years in a regionally dependent manner, drugs and methods to block 
transmission are failing.  Distribution and affordability of current therapies remains an obstacle 
due to the low socioeconomic status of regions were malaria is prevalent. Approximately 40% of 
the world’s populations live in areas where the risk of malaria transmission is high, typically the 
tropic zones located closer to the equator.  In addition to the young, the most affected by malaria 
are elderly folks, pregnant women and foreign born travelers.  
Currently there are only a limited number of drug choices for the treatment of malaria, the majority 
of which target the asexual blood stage parasite. These include chloroquine phosphate, atovaquone, mefloquine, quinine, quinidine, tetracycline, piperaquine, lumenfantrine, 
pyronaridine and clindamycin as designated by the World Health Organization. So there is a need 
for better more efficacious drugs that target either asexual or sexual stages of the parasite life cycle. 
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Literature Review: 
Significance of Malaria 
According to the World Health Organization (WHO) up to 200 million people per year become 
infected with malaria and this results in an estimated 0.6 million fatalities 1. The young are 
primarily at risk with the majority of deaths from malaria occurring in those that are five years  
 
old or younger and strikingly, in parts of Africa, results in up to 15% of deaths for the same age 
range. Malaria accounts for roughly 1 out of 100 deaths worldwide even though it is typically only 
found in areas of tropical climate 16. While the rate of malaria transmission has leveled off and 
even slightly declined in recent years in a regionally dependent manner, drugs and methods to 
block transmission are failing17,18.  Distribution and affordability of current therapies remains an 
obstacle due to the low socioeconomic status of regions were malaria is prevalent. Approximately 
40% of the world’s populations live in areas where the risk of malaria transmission is high, 
Figure 1. A world map showing malaria endemic areas. Shading reflects the % of population at 
risk. Red=80-100%; Orange=60-80%; Yellow=40-60%; Blue=20-40%; Green=0-20%; 
Grey=Not applicable. Adapted from malariavacccine.org  
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typically the tropic zones located closer to the equator (Figure 1.).  In addition to the young, the 
most affected by malaria are elderly folks, pregnant women and foreign born travelers.  
Malaria is a very ancient disease and has troubled tropical civilizations throughout history. The 
symptoms of malaria have a rapid onset with recurrent cycles of fever and chills, muscle aches, 
headaches, vomiting and jaundice but, may be extended to 8-10 months after the initial infected 
mosquito bite occurs 19.  
It was not until the late 1800’s when the underlying cause of malaria was discovered 20.  Until then 
most believed malaria came from foul smelling swampy areas 21 22.  In 1878 Dr. Alphonse Laveran, 
a French physician, identified the causative agent of malaria. Initially, malaria was believed to be 
caused by a bacterium 20.  Laveran was the first to observe what we now call gametocytes, the 
crescent shaped bodies, in the blood of a patient infected with Plasmodium falciparum 23.  While 
initial uptake of his discovery took some time, eventually Laveran was awarded the Nobel Prize 
for Medicine in 1907. Following this discovery, in the late 1890’s Ronald Ross, while studying 
avian malaria, identified the mosquito as the vector of P. falciparum for which he was also awarded 
the Nobel Prize. 
Global distribution of Plasmodium 
Plasmodium, a parasitic protozoon, has a complex life cycle involving both a mosquito vector and 
vertebrate host (Figure 3). There are six species that infect humans including P. falciparum, P. 
vivax, P. ovale(P. curtisi and P. wallikeri), P. knowlesi and P. malariae 24.  There are many other 
species which infect non-human primates and interspecies transmission is evidently possible25.  Of 
the six species, all but P. falciparum and P. vivax are relatively benign upon infection and of the 
two highly pathogenic species P. falciparum is responsible for the highest mortality rates.  
Importantly, the parasite lifecycle relies on the female mosquito which predicates it to be near 
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water and in the tropics or subtropics as mosquitoes require water for reproduction and cannot 
survive cold temperatures. Temperature is also an important factor in the development rate of the 
parasite extrinsically and is a key driver of vector (mosquito) development, bite rate, and survival 
within the mosquito all of which are decreased dramatically in colder climate26. Hence the major 
areas of infectious malaria are in an around the tropics.  P. vivax is an outlier in this case as it has 
genetically adapted to survive in lower temperature environments and can be found outside the 
tropic and subtropical regions27.  
Life cycle of Plasmodium falciparum The life cycle starts essentially at the point when a susceptible host is bitten by an infected female Anopheles mosquito. At that point the host is inoculated with sporozoites (Figure 3) which, are highly motile and quickly enter the host blood stream ultimately arriving at the liver. Here, the sporozoites invade the hepatocytes and, over the course of 5-21 days, mature to form exoerythrocytic schizonts each containing ~10,000 merozoites28.  When mature the schizont ruptures and the merozoites are released into the blood stream where they invade erythrocytes. During this intra-erythrocytic stage they undergo a cycle of asexual multiplication where each merozoite produces up to 20 new merozoites every two- three days.  The rupture of red blood cells and merozoite release is associated with the characteristic fever and chill symptoms of malaria29. This multiplication results in increased parasitaemia within the host which ultimately cause the pathogenic response elicited including fever, chills, vomiting, diarrhea, arrhythmia as well as multi-organ damage including renal failure 30.  
Gametocytes are the only stage of the parasite able to mediate transmission from the host to the 
mosquito vector. The trigger for sexual development of gametocytogenesis is unclear but a small 
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Stage I                Stage II           Stage III             Stage IV            Stage V           Stage V 
population of parasites invades red blood cells and switch to a pathway of sexual development.  In 
the case of P. falciparum gametocytes take 10 – 12 days to become mature and once they are 
mature can survive in an infected individuals blood stream for a period of time that isn’t precisely 
known but spans at least 7-14 days and may persist for weeks; even up to 50 days 31, 32. 
P. falciparum gametocytes go through five distinct stages ( I-V) as they mature, based on light and 
electron microscopy (Figure2 ) Mature stage V gametocytes have a characteristic crescent shape 
and only mature gametocytes are infectious to the mosquito vector 33, 34. 
When mature gametocytes are taken up by a female Anopheles mosquito, they are released from 
the red blood cell and undergo gametogenesis and the haploid gametes fuse to become diploid 
completing the sexual stage of the parasite's lifecycle. Over the course of 10-18 days the parasite 
goes through a number of development stages and maturation steps, resulting in the production of 
infectious haploid sporozoites that are ready for transmission to a new host when the mosquito 
next takes a blood meal.  
 
 
 
 
 
 
 
Figure 2. Stage progression of gametocytes in culture as viewed using Giemsa stain and bright 
field microscopy. Courtesy of Alice Butterworth. 
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Figure 3.  Life-cycle of the Plasmodium falciparum parasite, the etiological agent of human 
malaria. There are multiple stages of malaria infection as described in the text above. Notably the 
reproduction stage and transmission of the parasite from host to host involves the transfer of mature 
sexually differentiated gametocytes into the mosquito. 
 
 
Current Treatments 
 
Currently there are only a handful of drug choices for the treatment of malaria, the majority of 
which target the asexual blood stage parasite. As mentioned these include chloroquine phosphate, atovaquone, mefloquine, quinine, quinidine, tetracycline, piperaquine, lumenfantrine, 
pyronaridine and clindamycin as designated by the World Health Organization 35, 35b. In addition 
combination therapy is now more common and includes piperaquine, lumenfantrine and 
pyronaridine which are all are currently in use as fixed combination partners with artemisinin 
compounds. Optimally one would design a drug that defeats the malaria parasite resistance and 
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renders it incapable of further transmission. During the sexual stage of the parasite life cycle the 
gametocytes are transferred from host to vector where sexual reproduction and maturation renders 
the parasite infectious to the next round of hosts. So targeting via anti-gametocidal development, 
while likely having very little effect to reduce the parasite burden to the affected patient, may 
potentially prevent transmission.  
However, many genetic and metabolic changes occur during gametocyte maturation and while 
these are not fully understood it is clear that these impact on drug efficacy. Targeting mature 
gametocytes is problematic as they are refractory to most currently available antimalarial drugs 36, 
37. 
Primaquine is the only currently available antimalarial drug that is effective against stage V 
gametocytes, but there are problems associated with its safety in some populations. In particular, 
patients afflicted with Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) are 
already predisposed to spontaneous destruction of red blood cells. While this can be a genetic trait 
that protects some people from malaria infection, those that do get infected cannot take primaquine 
as it is known to cause haemolysis in these patients thereby acutely exasperating the condition. 
Tafenoquine is less toxic but is still only clinically useful for G6PD patients at a lower dose again 
justifying the need for better anti-gametocidal drugs38.  
Parasite resistance to current drugs 
One of the clearest reasons to develop novel drugs is the emergence of parasite resistance to the 
current regimen of anti-malarial drugs.  Genetic pressure on the parasite to evolve resistance to 
currently available drugs, aided in part by inappropriate therapeutic intervention, has created 
resistance to virtually all drugs and sadly now including the artimenisins5.  Recently the outcomes 
of the RTS,S phase 3 clinical trials for treatment with a malaria vaccine were published and 
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generally, efficacy was found in ~30% of the cases but, only in older infants when given multiple 
boosters 39.  However,  a truly effective vaccine is not expected to be available for another decade 
40.   
Importantly, drug resistance is defined as a right shift in the effective concentration response 
required for blocking malaria replication41.  More directly, patients with increasing resistance 
would result in less inhibition of parasite multiplication and a concomitant decrease in the 
effectiveness of the drugs.  Even further, patients with increasing resistance would result in less 
inhibition of parasite multiplication and a concomitant decrease in the effectiveness of the drugs.  
Rarely is there a direct correlation of in vivo to in vitro resistance which probably only exists in 
the case of chloroquine.42 In other cases testing artemisinin-resistance with quinine co-resistance 
emerging in P. falciparum malaria under in vivo artesunate pressure resulted in controversial experimental resistance which evolved in a rodent model system, the genetic correlates of which are not understood 43. While this complicates current use of prescribed therapies it also 
leaves opening to more easily test and determine if small molecule therapies maybe effective by 
testing in vitro. New leads can thus be expected to affect the target parasite so long as they are 
clinically safe for humans.  
Targets for Molecular Intervention 
PfM18AAP (protein, structure, localization and function) 
So there is a need for better more efficacious drugs that target either asexual or sexual stages of 
the parasite life cycle.  Some options are to target enzymes or proteins particular to only malaria 
parasites. One such target is the aspartal aminopeptidase enzyme classified as M18, or PfM18AAP. The PfM18AAP protease was previously identified as a potentially druggable therapeutic target by Trenholme et al and prior to this effort there were no known small-molecule 
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inhibitors of PfM18AAP. Previous reports have identified the phosphinic and phosphonic acid analogues of glutamate and aspartate, GluP and AspP, as modest amino acid–derived inhibitors of PfM18AAP in vitro.  As such experimental confirmation of its potential as a drug target has yet to be shown.   
There are at least eight aminopeptidases expressed by the clinically significant malaria parasites7. 
The specific role of malaria aminopeptidases are to cleave N-termini amino acids of short peptides 
as part of the final stages of hemoglobin digestion in the parasite lifecycle; thought to create a 
reservoir or nutrient pool of amino acids necessary for parasite biogenesis44.  The amino acid 
substrate used varies from methionine to leucine to aspartate. Some aminopeptidases have already 
been targeted for drug intervention; in particular the methionine aminopeptidases45, so headway 
has been made to identify inhibitors of these further substantiating them as druggable targets. 
PfM18AAP protein is expressed in all phases of the intra-erythrocytic stage of the parasite life 
cycle but, more so during the ring stage13.  It has been demonstrated as a functional protease 
obtained from the parasitic cytosol and has been shown to be exported to the parasitophorous 
vacuole indicating it may also have a role in addition to Hb degradation13.  Finally, Teuscher et al. 
2007, also demonstrated direct inhibition of recombinant M18AAP and parasite cytosolic M18 
protease in biochemical assays and using antisense inhibitors.   
Targeting the asexual and gametocyte stages 
New target strategies have been recently elucidated using novel modeling techniques, which 
predict four targets that have never been taken into account for anti-malarial drug design. These 
include modulating merozoite invasion of RBCs, increasing their transformation into gametocytes, 
decreasing the immune response to gametocytes, or a combined diminishment of the immune 
response while decreasing the recycling rate of the red blood cells46,47 . 
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The point of initiation for sexual differentiation starts at an early stage of asexual development; 
likely the ring or trophozoite stage. To elucidate further, during the erythrocytic ring stage, 
trophozoites mature into schizonts which eventually rupture releasing merozoites, each of those 
now maturing into a gametocyte. The trigger for the parasite to undergo sexual differentiation to 
form gametocytes is still under investigation but appears to be controlled by a transcriptional 
switch that may be regulated by a DNA binding protein called PfAP2-G48.  Commitment to 
sexually differentiated gametes is essential for the maintenance of the parasite lifecycle which is 
predicated by the uptake of such by the mosquito vector.  New drugs or molecular probes, i.e. a 
‘tool’ used to provide data or report on a biological or chemical target, usually within a biological 
or chemical assay, that either effectively and specifically kill gametocytes or block their sexual 
maturation would ultimately halt the parasites ability to replicate. So anti-gametocidals are indeed 
a viable path for drug discovery 49. 
Drug development pipelines 
The last two decades have spurned much in the way of drug discovery targeting multiple stages of 
malaria which have been supported in large part by the NIH and the Gates foundation. Still with 
resistance to the standard of care drugs, i.e. of the artesunate and quinine variety, arising in Africa there is an urgent need to fill the pipeline of drugs facilitating new treatments.  To that end 
there appears to be about 13 drugs in clinical development almost all of which are targeting the 
schizont stage of uncomplicated malaria.50,51  Note that 9 of these are in phase 2 development as 
of last year with a predicted chance of ~30-40% of making through the full regulatory approval.  
Ideally new treatments would be potent, fast acting, cost effective and present a broad safety profile 
for use even in children and pregnant women. In addition they would represent a high barrier to 
developing resistance. To this end researchers and pharma have been developing inhibitors that 
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act at various points of the parasite replication life cycle with an eye towards using them in 
combination with other existing or novel drugs. Briefly, a partial list of novel drugs, their target 
and point of inhibition are: 1) DSM265 from Takeda, Dihydroorotate dehydrogenase inhibitor, 
schizonticide 2) AQ-13, Immtech, modified 4-aminoquinoline, schizonticide 3) Methylene Blue 
by University of Heidelberg, glutathione reductase, schizonticide and gametocidal 4) Sevuparin 
(DF02) from Dilaforette, anti-adhesive, merozoite invasion 5) MMV 390048 from MMV and 
University of Cape Town, K inhibitor, schizonticide 6) P218 from MMV and Jannsen, DHFR, 
schizonticide 7) CDRI 97/78 from IPCA, trioxane, schizonticide 8) M5717 from MMV-Merck and 
University of Dundee, blocks protein synthesis by inhibiting EF2, multi-stage 9) SJ733 from 
MMV-University of Kentucky and Eisai, ATP4, schizonticide 10) ACT-451840 from Actelion, 
unknown mechanism of action, schizonticide.52  
 Challenges with currently available drug screening methods 
So as you can see from the above the current status of drug discovery for antimalarials is in a 
decent state yet challenges in how we find new inhibitors are profound as well. For example, most 
drug libraries have been trending towards identifying compounds with blood-stage activity but 
more recently there has been progress in the discovery of agents capable of preventing 
transmission using dedicated screening technologies such as those described in my thesis which 
specifically target gametogenesis. Other more universal challenges towards screening and drug 
discovery are also applicable here such as the high cost of scaling and performing large high 
throughput screening (HTS) efforts, the scalability and availability of reagents, the risk of not 
finding any inhibitors and generally the post HTS chemistry initiatives being lengthy and also 
costly.            
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Aims, hypotheses and objectives  
Two strategies of particular interest that are a focus of this thesis are to use a rational protein target 
based approach to screen the PfM18AAP and a more empirical approach to screen for inhibitors 
of mature late-stage gametocytes. These targets should be druggable from a small molecule 
perspective and represent a chance to determine if HTS is a viable path to find appropriate 
inhibitors that may become leads.  
The primary aims of my research are: 
1. To adapt, implement and develop the currently available low throughput techniques of the 
current assays targeting rPfM18AAP and mature late-stage gametocytes into robust HTS 
amenable assays. 
2. To perform large scale compound screening on divesified molecular collections against the 
targets of aim 1. 
3. To complete the evaluation of the outcomes of aim 2 via concentration response analysis 
of the most promising HTS hits including testing in post HTS specificity assays. 
4. To take lead like molecule through early medicinal chemistry efforts and develop novel 
molecular probes. 
My research hypotheses are: 
1. Targeting PfM18AAP for drug discovery, an aspartyl protease involved in the asexual 
erythrocytic stage of the malaria lifecycle which is critical for parasite replication will be 
done using good HTS practices, assay implementation and miniaturization. This will lead 
to high throughput screening that will identify potent and tractable hits thereby proving 
rPfM18AAP can be targeted for small molecule drug discovery. These hits will be further 
pursued and characterized in terms of specificity towards the target and chemically 
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modified such that, if successful, a molecular probe will be elucidated. 
2. Assay development to allow for phenotypic screening of whole cell late stage gametocytes, 
which are essential for sexual reproduction of the malaria parasite within the mosquito 
vector, will be scalable to 1536 well HTS.  Completion of a large scale HTS campaign will 
identify reproducible hits thereby validating this approach as a viable method for small 
molecule drug discovery. 
 
So in line with my aims and hypotheses, this project is divided into 2 different approaches to define 
or uncover new drugs active against either PfM18AAP or late stage gametocytes: 
1. Develop, optimize, miniaturize and screen and identify small molecule inhibitors the 
specifically effect the activity of PfM18AAP, an essential protein in the malaria life cycle. 
2. Develop, optimize, miniaturize and screen and to identify specific inhibitors against P. 
falciparum gametocytes. 
 
The first approach is investigated in Chapter 2 which describes the rational target based approach 
to identify compounds that inhibit the activity of PfM18AAP by high-throughput screening (HTS) 
of compound libraries and which yielded several series of potent compounds that demonstrate 
selectivity to the enzyme. Chapter 3 covers the subsequent effort of probe development of small 
molecules for the PfM18AAP initiative that includes mechanism of actions studies aimed 
specifically at this target. Chapter 4 summarizes a feasibility study and HTS using more emperical 
phenotypic approach incorporating a live dead assay in high density microtiter plates for the 
purpose of arresting transmission of Plasmodium falciparum via inhibition of gametocytes. 
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Chapter 2 
Targeting the Plasmodium falciparum protease –PfM18AAP  
Chapter 2 is directly derived from my manuscript demonstrating how I found compounds that 
inhibit the activity of rPfM18AAP by high-throughput screening.  
Please see Spicer, et.al.. Identification of Potent and Selective Inhibitors of the Plasmodium 
falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High Throughput 
Screening. J Biomol Screen. 2014 Mar 11. PMID: 24619116. PMC: 4641816.  (Appendix 1). 
 
My contribution to the authorship includes a substantive contribution to the following activities: 
1) conception and design of the project as well as execution of the experiments; 
2) analysis and interpretation of the research data on which the publication is based; 
3) drafting the publication as well as completing its submission as the communicating author. 
 
Summary: 
There are several potentially vulnerable points in the parasite lifecycle particularly during the 
blood stage as invasion of erythrocytes and subsequent parasite growth and development is critical 
for parasite survival. It is during this stage that P. falciparum uses protein-protein interactions and 
enzymatically driven processes to allow entry into, growth within, and escape from the human 
erythrocyte. One such enzyme is PfM18AAP, a ~67-kDa metallo-aminoipeptidase that 
oligomerizes and is the sole aspartyl aminopeptidase (AAP) present in the malaria parasite 8. 
PfM18AAP is thought to play an important role in the process of protein degradation and, working 
together with other exo-aminopeptidases, is believed to digest host hemoglobin, an important 
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source of amino acids for the parasite 53, 54.  PfM18AAP localises to both the parasite and the 
parasitophorus vacuole, suggesting that it may play a role in addition to haemoglobin degradation. 
Data from several laboratories suggest that the enzyme could also perform additional functions in 
the parasitophorus vacuole, the erythrocyte cytosol and at the infected erythrocyte membrane 
skeleton.PfM18AAP may also interact with the erythrocyte membrane protein, spectrin, 
presumably to regulate the integrity of the infected erythrocyte membrane skeleton during parasite 
growth, allowing for host cell expansion and parasite exit 55. 
Therapeutic approach to PfM18AAP inhibitors 
Antisense RNA knockdown experiments have shown that inhibition of intraerythrocytic 
PfM18AAP debilitates the malaria parasite, making it a promising drug target13.  Inhibitors of 
PfM18AAP will thus provide new tools to further our understanding of this enzyme’s function and 
increase the potential to develop therapies against P. falciparum transmission. Currently, there are 
no known small-molecule inhibitors of PfM18AAP. Previous reports have identified the 
phosphinic and phosphonic acid analogues of glutamate and aspartate, GluP and AspP, as modest 
amino acid–derived inhibitors of PfM18AAP in vitro. However, these amino acid derivatives do 
not reduce malaria growth in culture when tested at concentrations up to 100 uM 13.  Thus, the 
objective of this research program was to identify compounds that inhibit the activity of 
rPfM18AAP. Described here is my approach to discovering such inhibitors by high-throughput 
screening (HTS) of compound libraries, which yielded several series of potent compounds that, 
demonstrate selectivity to the enzyme. We identified two compounds that are noncompetitive 
inhibitors of rPfM18AAP and also inhibit the growth of P. falciparum in vitro. 
Methodology 
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Functionally active purified recombinant PfM18AAP was prepared at the University of 
Technology Sydney as previously described13. The Molecular Libraries Small Molecule 
Repository (MLSMR) library was provided by the National Institutes of Health’s Molecular 
Libraries Initiative.  Details regarding compound selection for this library can be found online 
(http://mli.nih.gov/mli/compound-repository/mlsmrcompounds/). 
Briefly, the MLSMR library is a highly diversified collection of small molecules (more than 50% 
of compounds exhibit molecular weights between 350 and 410 g/mol) comprising both synthetic 
and natural products, from either commercial or academic sources, that can be grouped into the 
three following categories: specialty sets of know bioactive compounds such as drugs and toxins, 
focused libraries aimed at specific target classes, and diversity sets covering a large area of 
chemical space 56. The enzymatic assay was originally developed by Dalton & Gardiner in a low 
throughput format and uses a fluorogenic peptide substrate (H-Glu-NHMec), which is incubated 
with purified recombinant PfM18AAP in the presence of test compounds. The assay was 
subsequently transferred to me, at Scripps Florida, was first recapitulated and subsequently 
implemented and optimized for 1536 well ultra-high throughput screening. In this assay, cleavage 
of the substrate by rPfM18AAP liberates the 7-amino-4-methylcoumarin fluorogenic leaving 
group (NHMec) from the peptide, leading to increased fluorescence (Figure 4). Enzymatic 
inhibitors block rPfM18AAP mediated cleavage of H-Glu-NHMec and liberation of the NHMec 
leaving group from the substrate, resulting in decreased fluorescence as measured at 340 nm 
excitation and 450 nm emission. To reduce the number of compounds that optically interfere with 
the measurement, initial (T0) and 90-min (T90) measurements of plate fluorescence were taken 
after addition of substrate.  Test compounds were assayed in singlicate at a final nominal 
concentration of 7uM. A stepwise assay protocol is presented in Supplemental Table S1. Further 
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details of this assay can be found at the PubChem AID 1822 
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1822).  
 
Figure 4: rPfM18AAP enzymatic assay principle. rPfM18AAP activity is determined by 
measuring the release of the 7-amino-4-methylcoumarin fluorogenic group (NHMec) from a 
peptide substrate (H-Glu-NHMec). Represented by the wavy line, cleavage of H-Glu-NHMec’s 
glutamic acid group by PfM18AAP liberates NHMec from the peptide, leading to increased well 
fluorescence. As designed the screening assay identifies compounds that inhibit rPfM18AAP-
mediated cleavage, resulting in decreased well fluorescence. 
 
 
rPfM18AAP HTS Campaign 
Following the miniaturization and optimization of the assay for 1536 well HTS, the first stage 
involved robotic validation and stability testing on a fully automated HTS platform. This was 
followed by singlicate screening against rPfM18AAP, the primary screen, and Cathepsin L1 
ON
H
O
Me
O
H2N
OH
O
OH2N O
Me
340nm Excitation 340nm Excitation 450nm Emmision
Low f luorescence
L-Glutamic acid 7-amino-4-methylcoumarin
(H-Glu-NHMec)
7-amino-4-
methylcoumarin
(NHMec)
 37 
(CTSL1) the primary counterscreen, at a final compound test concentration of 7 uM or 6 uM, 
respectively (see PubChem AIDs 1822 and 1906 for protocol details). The counterscreen 
incorporated for this assay used Cathepsin L1 which ultimately if inhibited may lead to host cell 
toxicity. Like the HTS for rPfM18AAP, this assay also exploits fluorogenic enzyme substrates. 
The final DMSO concentration was 0.7% (v/v) for the rPfM18AAP assay or 0.6% for the CTSL1 
assay. Well fluorescence was measured with a ViewLux plate reader (PerkinElmer, Waltham, 
MA), and the percent inhibition of each test compound was calculated on a per-plate basis as 
further described below. The numerical cutoff used to qualify active (“hit”) compounds was 
calculated as the average percentage inhibition of all compounds tested plus three times their 
standard deviation57.  The confirmation and counterscreens were run on selected hits in the same 
conditions as the primary screens, except that plates were assessed in triplicate and results for each 
compound were reported as the average percentage inhibition of the three measurements, plus or 
minus the associated standard deviation (PubChem AIDs 2170 and 2178).  For titration 
experiments, assay protocols were identical to those described above, with the exception that 
compounds were prepared in 10-point, 1:3 serial dilutions starting at a nominal test concentration 
of 74 uM and assessed in triplicate (PubChem AIDs 2195 and 2196).  To confirm activity of the 
best inhibitors, compounds were purchased as powder samples and tested in various secondary 
assays, including Ki determination, a malaria cell lysate assay and a P. falciparum parasite growth 
assay. 
Results 
The rPfM18AAP primary assay and CTSL1 counterscreen assay were implemented at a final 
volume of 5 microliters per well in 1536-well plates. The assays were screened against the entire 
MLSMR collection; 277,728 unique compounds were tested in both assays. All compounds were 
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screened at 7 uM for rPfM18AAP and 6 uM for CTSL1. For the rPfM18AAP screening assay, an 
IC100 of Zn(II) was used as a positive control for enzyme inhibition. Zinc has previously been 
shown to sufficiently suppress the enzyme activity here. The median of the wells containing test 
compounds was used as a negative control (i.e., IC0) where as the negative control wells contained 
enzyme and substrate along with vehicle only. Using these controls (Figure 5 ), the rPfM18AAP 
assay demonstrated robust screening statistics. It had an average signal-to-background ratio (S/B) 
of 3.42 +/- 0.89 and a Z′ of 0.84 +/- 0.04 (n = 241 plates)
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Figure 5 : rPfM18AAP (left panel) and CTSL1 (right panel) primary HTS assay performance. Positive control wells are shown as 
inverted green triangles (IC100 of ZnCl2 or Z-Phe-Ala-diazomethylketone). Results of compound wells (black triangles) and negative 
control wells (white squares) are also graphed. Calculated hit-cutoffs are indicated via dashed lines. Due to the high degree of compound 
activity found in the PfM18AAP assay, data for both HTS campaigns was normalized to the median of the compound wells (IC0) and 
the median of the respective IC100. Hence, the noticeable shift below 0% inhibition for rPfM18AAP assay. 
 
The CTSL1 assay was similarly robust; using Z-Phe-Ala diazomethylketone and the median of the wells containing test compounds as 
positive and negative controls, respectively, yielded an S/B of 3.61 +/- 0.26 and a Z′ of 0.88 +/- 0.04 over 247 plates. Any compound 
found active against rPfM18AAP but not active in the CTSL1 assay was prioritized for follow-up in the next round of testing. To further 
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enrich the data set for downstream follow-up studies, fresh aliquots of 2378 hit compounds 
demonstrating selective inhibition of rPfM18AAP were tested in triplicate against both assays. To 
confirm activity and selectivity, the primary HTS hit activity cutoffs were reapplied to each set of 
screening results. This yielded 125 compounds that confirmed selective activity against 
rPfM18AAP (i.e., their measured %inhibition was above the rPfM18AAP primary HTS activity 
cutoff and less than the CTSL1 counterscreen HTS activity cutoff). Fresh aliquots of these 
compounds were obtained for further characterization in titration (IC50) assays. All compounds 
yielded IC50 values of <10 uM in the primary assay and >10 uM in the counterscreen assay were 
considered active.  From the 125 compounds that demonstrated potent and selective inhibition of 
rPfM18AAP, a subset of compounds most tractable for structure-activity relationship (SAR) 
studies was purchased or resynthesized as powder samples. These powder samples were retested 
to confirm inhibition of purified recombinant PfM18AAP, as well as in malaria lysates, and also 
tested for their ability to inhibit P. falciparum parasite growth via 3H hypoxanthine incorporation. 
Two efficacious compounds were identified from this effort: CID 6852389, (S)-(+)-apomorphine 
hydrochloride hydrate, and CID 23724194, the hydrochloride salt of 4-[2-(acridin-9-
ylamino)ethyl]benzene-1,2-diol. CID 6852389 was found active in the P. falciparum lysate assay 
(84% efficacy at ≤5 uM; CID 23724194 was unavailable for testing). In the 3H hypoxanthine 
incorporation assay, CID 6852389 and CID 23724194 yielded 87% inhibition and 96% inhibition 
at 10 uM test concentrations, respectively. All compounds that inhibited parasite growth by >50% 
were titrated and retested as concentration-response curves in the same experiment. CID 6852389 
and CID 23724194 had the highest potency in these assays, with IC50 values of 4 uM and 1.3 uM, 
respectively. CID 6852389 and CID 23724194 were also assayed enzymatically to assess their 
mode of inhibition. Results of nonlinear regression analysis for Ki values were 3.39 +/- 0.36 uM 
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for CID 6852389 and 1.35 +/- 0.15 uM for CID 23724194. Mode of inhibition was determined by 
software-based comparison of fits method using competitive, noncompetitive, uncompetitive, and 
mixed models of inhibition. The preferred fit was the noncompetitive model of inhibition in all 
cases. In addition, the mode of inhibition was confirmed by steady-state velocity plots, semilog 
scale plots, and Lineweaver-Burke plots. As determined by these methods, both behave as 
noncompetitive inhibitors of rPfM18AAP (Figure 6).  
 
Figure 6: Determination of modes of inhibitor interaction using untransformed data analysis (first 
set of panels), semilog scale analysis (2nd set of panels) and Lineweaver-Burk analysis (bottom set 
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of panels) of potent and selective inhibitors rPfM18APP.  Both compounds exhibit non-
competitive inhibition. 
     
Results from previous primary screening assays were used to better understand possible off-target 
activities and liabilities of CID 6852389 and CID 23724194. When tested in similarly formatted 
enzymatic inhibition assays run at the Scripps Research Institute Molecular Screening Center 
(SRIMSC), these compounds were devoid of activity (cf. PubChem AIDs 1859, 1931, 651959). 
Similarly, where tested, they were also inactive in mammalian cytotoxicity (cf. PubChem AIDs 
1486, 1825) and bacterial viability (cf. PubChem AIDs 449731, 651606) screens, as well >100 
other primary screens run at the screening center. Remarkably, both compounds were found to be 
inactive in all cell-based screens tested at the SRIMSC, except for two serotonin receptor screens 
(cf. PubChem AIDs 612 and 504916). In summary, in silico evaluation of the activity of CID 
6852389 and CID 23724194 in a variety of cell-based and biochemical primary screening assays, 
including screens that used similar detection methodologies to the rPfM18AAP primary assay, 
indicated that the activity of these two compounds was specific to rPfM18AAP. 
Described here is my effort to identify small-molecule inhibitors of rPfM18AAP via an HTS 
approach. As formatted, both the rPfM18AAP primary screen and the CTSL1 counterscreen were 
highly amenable to automated screening in 1536-well microtiter plates, with a throughput of 
~20,000 compounds tested per hour. As indicated by Z′ and positive control IC50 values, excellent 
assay windows and consistent pharmacology were demonstrated throughout the HTS effort, which 
enabled facile identification of selective rPfM18AAP inhibitors. This screening approach 
identified 125 hit compounds with potent, selective inhibition of rPfM18AAP. Two of these 
compounds, CID 6852389 and CID 23724194, were found to be noncompetitive inhibitors of 
rPfM18AAP, with low-uM Ki values. As described previously58, I applied a “parallel” screening 
approach for the rPfM18AAP HTS, where the CTSL1 counterscreen was used to triage hits at each 
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stage of the rPfM18AAP campaign (Table 1). This was implemented since both the PfM18AAP 
and CTSL1 assays shared similar assay protocols, including the use of the same coumarin-based 
fluorophore for measurement of activity. CTSL1, a cysteine metalloproteinase, would be expected 
to be affected by divalent metal ions such as zinc or chelators of such. Divalent metal ions were 
not added as part of the reaction mix during the counterscreen assay, so identifying chelators is 
less likely, but similar in principle to rPfM18AAP, compounds that may coordinate metal atoms 
would be expected to affect the activity of CTSL1 and may be identified via this counterscreen. 
Table 1: rPfM18AAP uHTS Campaign Summary and Results. 
Step Screen type Target Number of 
compounds 
tested 
Selection 
criteria  
Number of 
compounds 
selected 
PubChem 
AID 
Assay statistics 
Z’ S/B 
1 
1 
Primary 
Primary 
Counterscreen 
PfM18AAP 
CTSL1 
291,944 
302,759 
>28.03% 
inhibition 
>16.63% 
inhibition 
3,522 
1,481 
1822 
1906 
0.84 ± 0.04 
0.88 ± 0.04 
3.42 ± 0.89 
3.61 ± 0.26 
2 Confirmation PfM18AAP 
 
2,378 >28.03% 
inhibition 
661 2170 0.87 ± 0.03 1.57 ± 0.04 
3 Counterscreen CTSL1 2,378 >16.63% 
inhibition 
7 2178 0.79 ± 0.01 3.53 ± 0.20 
4 Titrations PfM18AAP 
 
125 IC50<10µM 125 
 
2195 0.88 ± 0.02 2.03 ± 0.05 
CTSL1 125 IC50<10µM 0 2196 0.84 ± 0.03 4.12 ± 0.04 
5 Powder testing PfM18AAP 
 
76 >50% 
inhibition 
 
22 492974 NA NA 
Malaria Cell 
Lysate 
60 >50% 
inhibition 
 
28 492975 NA NA 
6 Follow-up Parasite 
Growth @ 
10µM 
76 >50% 
inhibition 
 
5 489015  NA NA 
Parasite 
Growth IC50 
 
5 IC50<5uM 2 489011 NA NA 
 *NA=Not 
Applicable 
 
 
To prioritize viable rPfM18AAP inhibitors, compounds that were active in both assays were 
triaged with the assumption that they optically interfered with the measurement of fluorescence in 
microtiter plates or were promiscuous inhibitors. The validity of this assumption is partially 
supported by the results of the  in silico analysis of CID 6852389 and CID 23724194; these 
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compounds were inactive not only in the CTSL1 counterscreen but also in all other similarly 
formatted coumarin based enzymatic assays run in the  screening laboratory. At the stage of 
potency assays, recapitulating this parallel approach enabled facile identification of selective 
rPfM18AAP inhibitors in the HTS data sets, allowing prioritization of compounds for labor-
intensive mechanistic assays. Following the HTS stage (i.e., step 4 in Table 1), 125 compounds 
remained that appeared to be selective inhibitors. At this stage, a chemical triage was applied and 
76 compounds were procured for testing in the lysate and parasite in vitro growth assay. Not all 
compounds were available in sufficient quantity for testing in both assays, in which case preference 
for usage was given to the parasite growth assay. Compounds that were active in both the parasite 
growth assay and the lysate assay (if available), were progressed for IC50 determination in the 
parasite growth assay. Of those five compounds, 6852389 and CID 23724194 were found to be 
the most potent. Although the CTSL1 results were used to identify selective inhibitors for the 
rPfM18AAP HTS effort, it is important to note several MLSMR compounds also selectively 
inhibited CTSL1 (see Figure 7). Alternatively, it is reasonable to assume that the criteria for 
prioritizing viable leads in the HTS effort may have removed genuine rPfM18AAP inhibitors. 
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Figure 7: Comparison of rPfM18AAP and CTSL1 primary screening results. The results of 
277,728 compounds (grey circles) are shown. The horizontal dashed line represents the CTSL1 
activity cutoff while the vertical dashed line represents the rPfM18AAP activity cut-off. Green 
circles represent the two “hit” compounds that were identified as part of the primary HTS. Arrows 
indicate the screening results for CID 6852389 and CID 23724194. 
 
For this reason, all results for the rPfM18AAP and CTSL1 screening assays have been placed in a 
publicly available database, PubChem (https://pubchem.ncbi.nlm.nih.gov/), which enables the 
reexamination and identification of compounds with apparent activity in either target’s screening 
assay. Cheminformatic analysis of the 125 hit compounds provides insight on the possible 
pharmacology of the hits identified from the HTS effort. These hits were subjected to analysis 
using the maximum common substructure hierarchical method of cluster analysis which I used to 
generate Figure 8.  This helped define molecules that are more appropriate for further pursuit in 
mechanism of action studies that will be discussed and described in Chapter 3. As represented by 
the cluster 9, catechols and catecholamines are well-known stimulants 59. 
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Derivatives of a 1,2,4 triazol-4-yl urea, found in cluster 3, have been shown to possess anti-
inflammatory and antibacterial activities 60. Cluster 6 and its 1,2,4 triazole derivatives have been 
associated with a wider range of pharmacology, including anti-inflammatory, antibacterial, 
antifungal, anticancer, analgesic, and antidepressant 61.  Finally, cluster 1 and its benzamide 
scaffold have derivatives with antagonistic activities against various receptors such as dopamine 
D2, 5-HT2, and 5-HT362.  Both CID 6852389 and CID 23724194 are nominally members of the 
“catechol” cluster 9. While catechols, in general, have been described as pan assay interference 
compounds (PAINS),63 there is contradicting evidence that this is the case here in which we search 
our entire database and found no activity in any of the  >100 assays tested in our laboratory.  Initial 
analysis of the catechols found here demonstrates a relatively flat SAR, which really only obviates 
that the catechol is important for activity. Figure 8 also demonstrates that most compounds from 
the 125 tested for IC50 associate into cluster 9, so clearly the catechol component must be important 
for activity. In addition, the nearly identical activity of CID 2215 and CID 6852389 clearly 
demonstrates that similar structures have reproducible activity, yet stereoselectivity cannot be fully 
ascertained due to lack of informative compound registration. 
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Figure 8: Clustering results of potent rPfM18AAP hits. Presented are the most common substructure, and respective second tier 
derivatives for the four most populous clusters. Cluster #9 (33 compounds total) is represented by a 1,2 catechol moiety; Cluster #3 (14 
total) is represented by a 1,2,4 triazol-4-yl-urea moiety; Cluster #6 (10 total) is represented by a (1,2,4 triazol-4-yl) acetamide moiety; 
and Cluster #1 (9 total) is represented by a benzamide moiety. CID 6852389 and CID 23724194 both belong to Cluster #9. 
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While these observations do not clarify whether the biological activity was simply due to 
“interference” (in other words, the catechol compounds acting as PAINS or that the catechol 
compounds might be coordinating the metal atoms that the enzyme requires to function, thus 
inhibiting the enzyme), we do know that rPfM18AAP reacts differently to various different metal 
ions. The enzyme is inhibited by zinc (>1 mM), which was employed as a positive control in 
screening assays but conversely is enhanced by cobalt and manganese. Therefore, the relationship 
of metal ion binding is complex64.  While the catechol group can chelate metal ions, which is 
important for their rPfM18AAP inhibitory activity, the compound structure is essential for 
specificity as the selected probes did not inhibit other malaria exometallo- aminopeptidases such 
as rPfM17LAP and rPfM1AAP (J. P. Dalton, unpublished data). Interestingly, another screening 
center has also reported that both CID 2215 and CID 6852389 inhibit a cell-based luciferase 
reporter assay to identify inhibitors of P. falciparum growth in vitro (http:// 
pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=504834) with IC50 values of similar potency. Still, 
taken together, there are clearly some additional and important determinations to be made to better 
understand how the molecules described in this study, in particular catechols, affect not only 
rPfM18AAP but also P. falciparum. Combined with other relevant biological data presented here, 
this provides a basis for future rPfM18AAP probe development. 
The rPfM18AAP inhibitors detailed here, CID 6852389 and CID 23724194, yield potent, 
reproducible results across laboratories in both biochemical and whole-cell studies. In addition, 
these heterocyclic compounds contain a basic nitrogen atom, a physicochemical property that is 
suspected to encourage lysosomotropism65.  They are the basis of continuing efforts to identify 
efficacious small molecule probes of rPfM18AAP, which are the subject of Chapter 3.  
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Chapter 3 
 
Subsequent Mechanism of Action Studies Targeting PfM18AAP Aimed at the Treatment 
and Prevention of Plasmodium falciparum  
 
Introduction 
Since there are several small molecule inhibitors of PfM1MAA and PfM17LAP, and very few 
small molecule inhibitors of PfM18AAP, we set out to identify small molecule inhibitors 
of PfM18AAP. Recall that rPfM18AAP is a target of interest as described previously in chapter 2 
and in the summary following this introduction. High throughput screening of the biochemical 
assay employing rPfM18AAP was also described in Chapter 2 and this is a continuing effort that 
includes small molecule testing and chemical optimization using other biochemical assays. 
Chapter 3 is directly derived from the manuscript describing how post HTS efforts, i.e. those 
described in Chapter 2, including mechanism of action studies and medicinal chemistry 
optimization, lead to the development and subsequent acceptance of a molecular probe that inhibits 
the activity of rPfM18AAP. Note a molecular probe is any molecule that achieves superior 
potency, i.e. inhibition than any other molecule identified as part of another scientifically published 
or patented prior art. In order for a molecule to be deemed a probe it must meet or surpass all probe 
criteria as approved by the National Institute of Health. Probe criteria for this target included the 
following: 1) rPfM18AAP potency demonstrating an IC50<10uM; 2) extracted PfM18AAP 
potency demonstrating and IC50<500nM; 3) 10X selectivity over rPfM1AAP; 4) 10X selectivity 
over PfM17LAP; 5) preferably < 1uM inhibition in the Pf parasite growth inhibition assay; 6) 
>50uM IC50 in the Vero cell cytotoxicity assay and 7) sufficient aqueous solubility at pH 7.4 and 
room temperature. Upon meeting these criteria one can assume a probe is a well validated lead 
molecule that is appropriate for transition into early phase clinical studies.  
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My contribution to the authorship includes a substantive contribution to the following activities: 
1) conception and design of the project as well as execution of a the medicinal chemistry 
support experiments including rPfM18AAP, rPfM17AAP, rPfM1AAP and the mammalian cell 
cytotoxicity assays 
2) analysis and interpretation of the research data on which the publication is based; 
3) drafting the portions of the publication for the results that I am responsible for and are 
described below9. 
Summary: 
Malaria is one of the most prevalent human parasitic diseases and is a global health issue 
accounting for >600,000 deaths annually. For survival, the Plasmodium falciparum (Pf) malaria 
parasite requires the action of a number of metallo-aminopeptidases that each display restricted 
amino acid specificities, including PfM1MAA (membrane alanine aminopeptidase), PfM17LAP 
(leucine aminopeptidase), and PfM18AAP (aspartyl aminopeptidase), which are thought to act in 
concert to degrade host erythrocyte hemoglobin that the parasite uses as a source of amino acid 
building blocks for the synthesis of its own proteins. Since there are several small molecule 
inhibitors of PfM1MAA and PfM17LAP, and very few small molecule inhibitors of PfM18AAP, 
we set out to identify small molecule inhibitors of PfM18AAP. High throughput screening of the 
biochemical assay employing rPfM18AAP was described in Chapter 2 and this effort now includes 
small molecule testing and chemical optimization using other biochemical assays. These include 
native PfM18AAP, recombinant Fasciola hepatica cathepsin L1 (rFhCTSL1), rPfM1MAA, 
rPfM17LAP, and rhM18, and cell-based parasite growth inhibition and cytotoxicity assays which 
were used to identify CID 23724194 (from the NIH MLSMR) as a viable starting point for 
medicinal chemistry optimization. Two rounds of structure-activity relationship studies were 
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performed to generate the probe ML369 (CID 56846691) (Figure 9). The probe is the best-in-class 
small molecule inhibitor of PfM18AAP; however, certain liabilities discussed in detail in the probe 
report limit its usefulness. When the probe is used as recommended, the probe is “fit-for-purpose” 
and should be useful for advancing the field. 
 
Figure 9. The probe ML369  
 
Methodology 
Recombinant enzymes 
Recombinant PfM18AAP, PfM17LAP, PfM1AAP, and human M18 were prepared at the 
University of Technology, Sydney, as described previously13,66. Recombinant cathepsin L of the 
parasitic helminth Fasciola hepatica was prepared in the same laboratory as described 
previously67. 
Native PfM18AAP enzyme 
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Parasite extracts containing PfM18AAP were prepared at the University of Technology, Sydney, 
as described previously13. 
Assays 
A list of the relevant assays and corresponding PubChem assay identifier numbers (AIDs) is 
provided in Table 2- 
(https://www.ncbi.nlm.nih.gov/books/NBK179825/table/ml369.t13/?report=objectonly) which is 
also represented below: 
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Table 2: List of all Assay Identifiers and Metadata Associated to Each Stage 
PubChem 
AID No. Assay Format Assay Target 
Test Compound 
Concentration 
Range (µM) 
Number of Compound 
Samples Tested 
Performance 
Site Stage 
1855 Summary rPfM18 inhibitor project NA NA SRIMSC NA 
1822 Biochemical rPfM18 inhibition assay 7.35 291,944 SRIMSC Primary Screen 
1906 Biochemical rCTSL1 inhibition assay 5.96 302,759 SRIMSC Primary Screen 
2170 Biochemical rPfM18 inhibition assay 7.35 2,378 SRIMSC Primary Screen 
2178 Biochemical rCTSL1 inhibition assay 5.96 2,378 SRIMSC Primary Screen 
2195 Biochemical rPfM18 inhibition assay 0.0037-73.5 125 SRIMSC Primary Screen 
2196 Biochemical rCTSL1 inhibition assay 0.003-59.6 125 SRIMSC Primary Screen 
492974 Biochemical rPfM18 inhibition assay 5 76 Dalton Lab Hit Validation 
492975 Biochemical ePfM18 inhibition assay 5 60 Dalton Lab Hit Validation 
489015 Cell-based Pf growth inhibition assay 10 76/TBD Gardiner Lab Hit Validation/SAR 
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PubChem 
AID No. Assay Format Assay Target 
Test Compound 
Concentration 
Range (µM) 
Number of Compound 
Samples Tested 
Performance 
Site Stage 
489011 Cell-based Pf growth inhibition assay 1-25 8/TBD Gardiner Lab Hit Validation/SAR 
588678 Biochemical rPfM18 inhibition assay 0.19-100 63 SRSBSC SAR 
602222 Biochemical rPfM18 inhibition assay 0.19-100 10 SRSBSC SAR 
624177 Biochemical rPfM18 inhibition assay 0.19-100 45 SRSBSC SAR 
588680 Biochemical rPfM1 inhibition assay 0.19-100 63 SRSBSC SAR 
602219 Biochemical rPfM1 inhibition assay 0.19-100 10 SRSBSC SAR 
624176 Biochemical rPfM1 inhibition assay 0.19-100 45 SRSBSC SAR 
588679 Biochemical rPfM17 inhibition assay 0.19-100 63 SRSBSC SAR 
602220 Biochemical rPfM17 inhibition assay 0.19-100 10 SRSBSC SAR 
624175 Biochemical rPfM17 inhibition assay 0.19-100 45 SRSBSC SAR 
588696 Biochemical rhM18 inhibition assay 0.19-100 63 SRSBSC SAR 
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PubChem 
AID No. Assay Format Assay Target 
Test Compound 
Concentration 
Range (µM) 
Number of Compound 
Samples Tested 
Performance 
Site Stage 
602221 Biochemical rhM18 inhibition assay 0.19-100 10 SRSBSC SAR 
624174 Biochemical rhM18 inhibition assay 0.19-100 45 SRSBSC SAR 
588714 Cell-based Vero cytotoxicity assay 0.19-100 63 SRSBSC SAR 
602225 Cell-based Vero cytotoxicity assay 0.19-100 15 SRSBSC SAR 
624205 Cell-based Vero cytotoxicity assay 0.19-100 TBD SRSBSC SAR 
NA = not applicable 
 
The following flowchart (Figure 10) summarizes the results for the high-throughput screening campaign that was described in chapter 
2 and is pertinent to the assays described in the first 7 AIDs shown in table 2.
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Figure 10. Critical Path for Primary Screening of rPfM18AAP 
 
Please see the (https://www.ncbi.nlm.nih.gov/books/NBK179825/#ml369.app2) for the detailed 
assay protocols which are also detailed below. Also note the definition of EC50 and IC50 is 
technically different with EC50 being the effective concentration that yields fifty percent activity 
and IC50 is the inhibitory concentration that yields fifty percent activity. For the purpose of this 
thesis they may at times be used interchangeably. For brevity and because the detailed protocols 
for AIDs 1855 -2196 are already described in chapter 2, only details for the protocols associated 
to the probe development work in this chapter are shown below (AIDs 492974 through 624205 
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from table 2 above).
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Additional Mode of Action, Probe Synthesis and Analytical Quality Control Activities.  
The work described below in sections 2.1.7 through section 2.2, while critical to the successful 
probe development effort of ML369, was not performed by me and hence is included to 
demonstrate knowledge around the subject matter but, is limited in detail because it is not a result 
of my direct efforts. However complete information is easily attained using the listed pubchem 
AIDs and also in the download of the full probe report. 
Fluorescence-based rPfM18AAP Confirmatory Biochemical Assay (Hit Validation Assay 
AID No. 492974) 
The purpose of this assay is to determine inhibitory activity of powder samples of compounds for 
recombinant P. falciparum M18AAP. This assay was performed in the labs of the assay provider, 
John P. Dalton 
Fluorescence-based Malarial Cell Lysate PfM18AAP Confirmatory Biochemical Assay (Hit 
Validation Assay AID No. 492975) 
The purpose of this assay is to determine inhibitory activity of powder samples of compounds for 
PfM18AAP in a malarial cell lysate. This assay was performed in the labs of the assay provider, 
John P. Dalton. 
Radiolabel-based Pf Parasite Growth Cell-based Assay (Hit Validation and SAR Assays AID 
No. 489015) 
The purpose of this assay is to determine the ability of powder samples of inhibitor compounds to 
inhibit the growth of Plasmodium falciparum in its asexual erythrocytic stage. For the purposes of 
hit validation and SAR optimization, this assay was performed in the labs of the assay provider, 
Donald Gardiner. 
Radiolabel-based Pf Parasite Growth Cell-based Assay (Hit Validation and SAR Assays AID 
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No. 489011) 
The purpose of this assay is to determine the potency of a powder sample of an inhibitor compound 
identified in a previous assay to inhibit the growth of Plasmodium falciparum in its asexual 
erythrocytic stage. For the purposes of hit validation and SAR optimization, this assay was 
performed in the labs of the assay provider, Donald Gardiner. 
rPfM18AAP QFRET-based Concentration-response Biochemical High Throughput Assay 
(SAR Assay AID Nos. 588678, 602222, 624177) 
The purpose of this assay is to determine concentration response curves for compounds to support 
on-target SAR studies. This assay was performed at the Southern Research Specialized 
Biocontainment Screening Center. 
rPfM1MAA QFRET-based Countersceeen Concentration-response Biochemical High 
Throughput Assay (Counterscreen Assay AID Nos. 588680, 602219, 624176) 
The purpose of this assay is to determine concentration response curves for compounds to support 
off-target-selectivity SAR studies. This assay was performed at the Southern Research Specialized 
Biocontainment Screening Center. 
rPfM17LAP QFRET-based Countersceeen Concentration-response Biochemical High 
Throughput Assay (Counterscreen Assay AID Nos. 588679, 602220, 624175) 
The purpose of this assay is to determine dose response curves for compounds to support off-
target-selectivity SAR studies. This assay was performed at the Southern Research Specialized 
Biocontainment Screening Center. 
rhM18 QFRET-based Countersceeen Concentration-response Biochemical High 
Throughput Assay (Counterscreen Assay AID Nos. 588696, 602221, 624174) 
The purpose of this assay is to determine dose response curves for compounds to support off-
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target-selectivity SAR studies. This assay was performed at the Southern Research Specialized 
Biocontainment Screening Center. 
Vero Cell-based Concentration-response Cytotoxicity Assay (Counterscreen Assay AID Nos. 
588714, 602225, 624205) 
The purpose of this assay is to determine dose response curves for compounds to determine 
cytotoxicity associated to mammalian cells, in this case Vero cells,  for use in determining which 
compounds to proceed with in SAR studies. This assay was performed at the Southern Research 
Specialized Biocontainment Screening Center. 
Probe Chemical Characterization 
All of the probe synthesis and chemical characterization was done by the Kansas University 
Specialized Chemistry Screening Center. Specifically ML369 was synthesized in two steps from 
commercially available materials as described in 
(https://www.ncbi.nlm.nih.gov/books/NBK179825/#ml369.app3) and its spectral data are in 
provided in (https://www.ncbi.nlm.nih.gov/books/NBK179825/#ml369.app5). This effort 
included aqueous solubility testing and the probe compound ML369 was found to have a solubility 
of 2.9 micrograms per milliliter, or 9 uM, under assay buffer conditions, which is 2X and 7X the 
IC50 values in the biochemical and cell-based rPfM18AAP and PfM18AAP inhibition assays, 
respectively. Aqueous stability and thiol stability was also assessed in 1:1 acetonitrile:PBS (no 
antioxidants or other protectants, DMSO concentration 1%, room temperature). The probe 
compound ML369 was found to be moderately stable in 1:1 acetonitrile:PBS, whereby 75% of the 
compound remained after 48 hours, which is the timeframe for the radiolabel-based Pf parasite 
growth cell-based inhibition assay  
Submission of the Probe and Analogues to the NIH MLSMR 
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Samples of the probe and five analogues were submitted to the NIH MLSMR compound collection 
on March 21, 2013.  
Results 
Summary of Screening Results 
Assay validation and high-throughput screening for the project were carried out as collaboration 
between the Scripps Research Institute Molecular Screening Center, and the assay providers, John 
P. Dalton and Donald L. Gardiner. Professor Dalton and his team produced purified, and 
functionally characterized the recombinant Plasmodium falciparum (rPfM18AAP) and 
recombinant cathepsin L (rCTSL1) enzymes which were used by the SRIMSC team. The flowchart 
shown above summarizes the results for the high-throughput screening campaign (Figure 10). 
The approximately 300k compounds in the NIH Molecular Libraries Small Molecule Repository 
(MLSMR) were screened in singlicate at 7.35 uM. The results and statistics for the screen are 
described schematically in the following figure (Figure 11) 
 
Figure 11: rPfM18AAP primary HTS assay performance. Positive control wells are shown as 
green circles (IC100 of ZnCl2 or Z-Phe-Ala-diazomethylketone). Results of compound wells (black) 
and negative control wells (blue) are also graphed. Calculated hit-cutoff is indicated via dashed 
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lines. Due to the high degree of compound activity found in the rPfM18AAP assay, data was 
normalized to the median of the compound wells (IC0) and the median of the respective IC100. 
Hence, the noticeable shift below 0% inhibition for rPfM18AAP assay. 
 63 
Of the approximately 300k compounds screened for rPfM18AAP inhibition at 7.35 uM, 3,522 
compounds showed inhibition >28% and were considered to be active. These screening results are 
captured in PubChem AID 1822. Of the approximately 300k compounds screened for cathepsin 
L1 inhibition in singlicate at 5.96 uM, 1,481 compounds showed inhibition >16% and were 
considered to be active. These screening results are captured in PubChem AID 1906. 
The most active 2,500 compounds from the primary screen for rPfM18AAP inhibition, which were 
considered to be inactive in the primary counterscreen against capthepsin L1, were ordered from 
the NIH MLSMR as DMSO stock solutions, and 2,378 of the 2,500 compounds were available 
and were delivered to the SRIMSC for confirmatory screening. 
Of the 2,378 compounds screened for rPfM18AAP inhibition in triplicate at 7.35 uM, 661 
compounds showed inhibition >28% and were considered to be active. These screening results are 
captured in PubChem AID 2170. Of the 2,378 compounds screened against cathepsin L1 in 
triplicate at 5.96 uM, 7 compounds showed inhibition >16% and were considered to be active. 
These screening results are captured in PubChem AID 2178. 
The most active 128 compounds from the confirmatory, single-concentration-in-triplicate screen 
for rPfM18AAP inhibition, which were inactive in the confirmatory, single-concentration-in-
triplicate counterscreen for cathepsin L1 inhibition, were ordered from the NIH MLSMR as 
DMSO stock solutions, and 125 of the 128 compounds were available, and were delivered to the 
SRIMSC for concentration-response confirmatory screening. 
Of the 125 compounds screened for rPfM18AAP inhibition in 10-point concentration-response 
between 0.0037 and 73.5 uM, all 125 showed IC50 values < 10 uM, and were considered to be 
active. These screening results are captured in the PubChem AID 2195. Of the 125 compounds 
screened against cathepsin L1 in 10-point concentration-response between 0.003 and 59.6 uM, 
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none of the 125 showed IC50 values < 10 uM and all were considered to be inactive. These assay 
results are captured in the PubChem AID 2196. 
Hit validation for the project using compound samples from the solid physical state was carried 
out as collaboration between the chemistry center, KU SCC, and the assay providers, John P. 
Dalton and Donald L. Gardiner. In parallel, the Dalton team performed percent-inhibition 
biochemical assays using recombinant PfM18AAP and PfM18AAP in soluble extracts of the 
malaria parasite, while the Gardiner team performed percent-inhibition and concentration-
response parasite growth inhibition cell-based assays. 
All of the 125 compounds considered active against rPfM18AAP and inactive against cathepsin 
L1 were suggested for follow-up hit validation using compound samples from the solid physical 
state. While many of the 125 compounds are considered PAINS68, 63, the assay providers suggested 
that many compounds used to treat malaria might be considered PAINS and that PAINS should 
not be excluded from hit validation. Of the 125 compounds, 76 compounds were purchased or 
synthesized, purified, analyzed, and shipped by the University Of Kansas Specialized Chemistry 
Center to the assay providers, John P. Dalton and Donald L. Gardiner. 
Of the 76 compounds screened for confirmatory activity against the recombinant PfM18AAP in 
singlicate at 5 uM, 22 compounds showed inhibition >50% and were considered to be active. These 
screening results are captured in the PubChem AID 492974. Of the 60 compounds screened for 
confirmatory activity against the PfM18AAP in soluble extracts of malaria in singlicate at 5 uM, 
28 compounds showed inhibition >50% and were considered active. These screening results are 
captured in PubChem AID 492975. 
Of the 76 compounds screened for parasite growth inhibition in triplicate at 10 uM, 8 compounds 
showed inhibition >50% and were considered to be active. These screening results are captured in 
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the PubChem AID 489015. Of the 8 compounds screened for parasite growth inhibition in 5-point 
concentration-response between 1 and 25 uM, 5 showed IC50 values < 5 uM, and were considered 
to be active. These screening results are captured in PubChem AID 489011. 
The top 5 compounds of interest resulting from the primary screening and hit validation studies 
are shown in the Table 3. In selecting a compound chemotype for medicinal chemistry 
optimization, the aqueous solubility and biological promiscuity (i.e., lack of biological 
promiscuity, as determined from a survey of PubChem) for the top 5 compounds were considered 
in addition to the requirement for selectivity and reasonable activity in the biochemical and cell-
based assays. Ultimately, the compound CID 23724194 (Entry 1) was selected by the greater team 
for medicinal chemistry optimization. This served as the starting point for SAR optimization which 
is detailed in tables 4-13 below; ultimately leading to the identification of the molecular probe 
ML-369. One structural feature worth noting, common to all of the top compounds of interest, is 
a putative zinc-binding domain (i.e., catechol or other), consistent with the nature of PfM18AAP 
as a metallo-aminopeptidase. 
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Table 3 Top 5 compounds of interest from the primary screening and hit validation studies. 
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Figure 12. Concentration-response Curves for the Probe (ML369). ML369 (CID 56846691, SID 
135378316) was tested across a range of concentrations up to 100 μM in the primary and several 
secondary assays. Concentration response data was analyzed using a four parameter logistic fit to 
the data (Excel Fit equation 205) with the maximum and minimum locked at 100 and 0. From 
these curves IC50 values were calculated. (A) rPfM18AAP biochemical assay (AID 624177), IC50 
= 4.6 μM; (B) rPfM1MAA biochemical assay (AID 624176), IC50 = 74.9 μM; (C) rPfM17LAP 
biochemical assay (AID 624175), IC50 = 37.7 μM; (D) rhM18 biochemical assay (AID 624174) 
IC50 = 4.43 μM; (E) Vero cell cytotoxicity assay (AID 624205) EC50 > 50 μM 
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Dose Response Curves for Probe 
As shown in Figure 12, ML369 (CID 56846691, SID 135378316) was tested across a range of 
concentrations up to 100 uM in the primary and several secondary assays. Concentration response 
data was analyzed using a four parameter logistic fit to the data (Excel Fit equation 205) with the 
maximum and minimum locked at 100 and 0. From these curves IC50 values were calculated. (A) 
rPfM18AAP biochemical assay (AID 624177), IC50 = 4.6 uM; (B) rPfM1MAA biochemical assay 
(AID 624176), IC50 = 74.9 uM; (C) rPfM17LAP biochemical assay (AID 624175), IC50 = 37.7 
uM; (D) rhM18 biochemical assay (AID 624174) IC50 = 4.43 uM; (E) Vero cell cytotoxicity assay 
(AID 624205) EC50 > 50 uM 
Scaffold/Moiety Chemical Liabilities 
As a reminder please note a molecular probe is any molecule that achieves superior potency, i.e. 
inhibition than any other molecule identified as part of another scientifically published or patented 
prior art. In order for a molecule to be deemed a probe it must meet or surpass all probe criteria as 
approved by the National Institute of Health including sufficient aqueous solubility at pH 7.4 and 
room temperature. Upon meeting these criteria one can assume a probe is a well validated lead 
molecule that is appropriate for transition into early phase clinical studies.  
The aqueous solubility for ML369 was determined to be 2.9 µg/mL (9.1 uM) in phosphate buffered 
saline (PBS, pH 7.4) containing 1% DMSO, which is 2X and 7X the IC50 values in the biochemical 
and cell-based rPfM18AAP and PfM18AAP inhibition assays, respectively. The probe is stable in 
1:1 acetonitrile:PBS, with 100% remaining after 8 hours and 75% remaining after 48 hours, which 
is the timeframe for the radiolabel-based Pf parasite growth cell-based inhibition assay. The probe 
was determined to be moderately stable to thiol (DTT), with 70% remaining after 8 hours. While 
the catechol functional group may be a liability due to its perceived toxicity, a number of currently 
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prescribed drugs contain the catechol functional group, and methods of circumventing the toxicity 
of catecholics have been suggested59. 
SAR Tables 
SAR optimization for the project was carried out as collaboration between the chemistry center, 
the KU SCC, the assay providers, John P. Dalton and Donald L. Gardiner, and the screening center, 
the Southern Research Specialized Biocontainment Screening Center. In parallel, the Gardiner 
team performed percent inhibition and concentration-response parasite growth inhibition cell-
based assays, while the SRSBSC team performed the biochemical rPfM18AAP, rPfM1MAA, 
rPfM17LAP and hM18 assays, and the Vero cell cytotoxicity assays. 
During the primary screening and compound hit validation stages of the project, the main drivers 
for compound prioritization were activity against the rPfM18AAP and ePfM18AAP in 
biochemical assays, selectivity against cathepsin L1 in a biochemical assay, activity against the 
malaria parasite in a red blood cell cell-based assay, and, finally, acceptable aqueous solubility and 
biological promiscuity. Based on these considerations, the catechol-containing compound CID 
23724194 was chosen for medicinal chemistry optimization. The main project drivers during the 
SAR optimization stage of the project were activity against the rPfM18AAP in a biochemical 
assay, selectivity against rPfM1MAA, rPfM17LAP and rhM18 in biochemical assays, activity 
against the malaria parasite in a red blood cell cell-based assay, and lack of activity in a Vero cell 
cytotoxicity assay. While achieving 10-fold selectivity for the rPfM18AAP versus the rPfM1MAA 
and rPfM17LAP was considered to be quite likely, achieving selectivity against the rhM18 was 
considered unlikely. Although there is only a low level of amino acid sequence identity between 
the rPfM18AAP enzyme and the human orthologue (18%), suggesting that selectivity of 
compound binding for the malaria enzyme might be achieved, significant conservation exists 
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between the active sites of the malaria and human enzymes. For example, three histidine residues 
(His-94, His-170, and His-440) which are predicted from site-directed mutagenesis studies to be 
critical for enzymatic activity and another (His-352) essential for stabilization of the quaternary 
structure of human M18 are conserved in the malaria enzyme. In fact, when the compound CID 
23724194/CID 53464134 was tested across the suite of assays that would be used to drive SAR, 
the above predictions were substantiated, as modest selectivity was observed for the inhibition of 
rPfM18AAP versus rPfM1MAA and rPfM17LAP, and poor selectivity was observed versus the 
human M18 orthologue (Table 4). 
Table 4. Activity for CID 23724194, the starting point for SAR optimization. 
 
From this starting point, the team's goal was to improve upon CID 23724194 over two rounds of 
SAR optimization. For the purpose of SAR optimization, the team divided the compound into three 
domains: (i) a putative zinc-binding domain, (ii) a linker domain, and (iii) a heterocycle domain 
(Figure 13). 
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Figure 13 
For the first round of SAR the team chose to survey the effect of gross structural changes to these 
three domains, in isolation, and in combination. As shown in Table 5, while changes to the 
heterocycle domain were tolerated, none of the changes led to increased activity against 
rPfM18AAP. Although the selectivity against rPfM1MAA and rPfM17LAP was largely 
unchanged, the selectivity against rhM18 was observed to increase quite dramatically for 
alternative heterocycles (Table 5, entries 1 and 5). 
 72 
 
Table 5. Round 1 SAR and Changes to the Heterocycle Domain. The parent compound is included (top table) for comparison. 
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As shown in Table 6, changes to the length of the linker domain had a profound effect on activity across the biochemical assays. 
Shortening the linker by one carbon atom abolished activity across the biochemical assays (Table 6, entry 1) and lengthening the linker 
by one carbon atom diminished the activity across the biochemical assays (Table 6, entry 2). 
Table 6. Round 1 SAR and Changes to the Linker Domain. The parent compound is included (top table) for comparison. 
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For the compounds listed in Table 7, changes to the putative zinc-binding domain were explored. Exchanging the catechol for a phenol 
resulted in complete loss of activity across the biochemical assays (Table 7, entry 1). Replacing the catechol moiety using the 3-hydroxy-
4-pyridone moiety, a zinc-binding group popularized by Cohen69, also resulted in complete loss of activity across the biochemical assays 
(Table 7, entry 2). Replacing the catechol moiety with the carboxyl group resulted in complete loss of activity across the biochemical 
assays, too (Table 7, entries 3 and 4). 
Table 7. Round 1 SAR and Changes to the Putative Zinc-binding Domain. The parent compound is included (top table). 
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As shown in Table 8, as was the case for changes to the heterocycle domain only (Table 5), while simultaneous changes to the heterocycle 
and linker domains were tolerated, none of the changes led to increased activity against rPfM18AAP. Although the selectivity against 
rPfM1MAA and rPfM17LAP was largely unchanged, the selectivity against hM18 was observed to increase quite dramatically (versus 
the initial compound hit) in some cases (Table 8, entries 3 and 5). 
Table 8. Round 1 SAR and Simultaneous Changes to the Heterocycle and Linker Domains. 
 
A curious discrepancy is apparent from inspection of the data in the Tables 5, 6, 7, and 8, which is that there does not appear to be a 
very good correlation between the activity of the compounds against rPfM18AAP and their activity in the parasite growth inhibition 
assay. One striking example is entry 2 in the Table 7, which shows no activity across the various biochemical assays and no cytotoxicity 
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against Vero cells, yet has an EC50 of 6 uM in the parasite growth inhibition assay. In general, across the larger set of compounds in 
these tables, this discrepancy might be explained by potential off-target activity. With respect to entry 2, Table 7, specifically, it is 
possible that the activity observed for this compound might result from the off-target iron-chelating ability of the 3-hydroxy-4-pyridone 
moiety65. 
The curious discrepancy between the activity of some compounds against rPfM18AAP and their activity in the parasite growth inhibition 
assay was further highlighted by the purposeful circumstance whereby the Gardiner team performed percent inhibition and 
concentration-response parasite growth inhibition cell-based assays on compounds independent from the SRSBSC team, which 
performed the biochemical rPfM18AAP, rPfM1MAA, rPfM17LAP and hM18 assays, and the Vero cell cytotoxicity assays. In other 
words, all compounds, even compounds that were inactive across the biochemical assays, were tested purposefully for inhibition of 
parasite growth. Table 3.4.6 lists the biological activity for target compounds containing the catechol functional group and the respective 
penultimate target compounds containing the O,O-dimethyl catechol functional group from which the final compounds were prepared. 
In a number of cases, specifically for entries 5, 8, and 14, Table 9, even though the compounds were inactive across the various 
biochemical assays and non-toxic to Vero cells, the compounds showed significant activity in the parasite growth inhibition assay. With 
respect to these entries, it is possible that the activity observed for these compounds might result from off-target hemozoin capping, 
much as is the case for chloroquine, which shares the 4-aminoquinoline heterocycle with these compounds70. 
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Table 9. Round 1 SAR and Final Catechol-containing and Penultimate O,O-Dimethyl Catechol-containing Compounds. 
 
Table 9. Continued 
 78 
  
Table 9. Continued 
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Table 9. Continued 
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On the other hand and most importantly, compounds from the first round of SAR, specifically, 
entries 1 and 5, Table 5, and entry 5, Table 8, showed the expected correlation between activity in 
the biochemical assay and activity in the parasite growth inhibition assay (see Table 9 and compare 
the activity for entries 2, 6, and 16 to the activities for their respective O,O-dimethyl catechol 
counterparts, listed in the rows immediately above each entry). 
It should be noted, however, that the correlation between activity in the biochemical assays and 
the activity in the parasite growth inhibition assay may be confounded by the selective 
accumulation of appropriately basic inhibitor compounds in the low-pH 71 parasitophorous vacuole 
of the parasite65, the site in which PfM18AAP is believed to function (the pH for the red blood cell 
cytoplasm and parasite cytoplasm is estimated as 7.0-7.2 and 6.8-7.0, respectively 72). 
With respect to the second round of SAR, the results for only a small subset of the compounds 
synthesized will be highlighted, where the results augment (as opposed to reproduce) the SAR 
story from the first round. 
For the second round of SAR the team chose to build on the observation from the first round that 
selectivity against rhM18 was observed to increase quite dramatically for alternative 
heterocycles (Table 5, entries 1 and 5) and for simultaneous changes to the heterocycle and 
linker domains (Table 8, entries 3 and 5). Armed with this specific information and the general 
precedent that conformational constraint may influence selectivity, compounds where the N-
atom of the linker domain was joined to a carbon atom of the linker domain were targeted for 
synthesis. Examples of these compounds are shown in the Table 10. In fact, across the three 
compounds shown in Table 10, the selectivity across the biochemical assays is improved, 
relative to the starting compound hit (Table 4).
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Table 10. Round 2 SAR and Constrained N-Atom/Linker Analogues. Parent compound included (top table). 
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The discrepancy between the activity of some compounds against rPfM18AAP and their activity in the parasite growth inhibition assay 
continued for this set of compounds, as may be seen in Table 11 (Parent compound included (top table). 
Table 11. Round 2 SAR and Final Catechol-containing and Penultimate O,O-Dimethyl Catechol-containing Compounds.  
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Based on these two rounds of SAR optimization, the compounds in Table 12 were considered as probe candidates (catechol-containing 
compounds, only). While the activity and selectivity for the compounds varies across the biochemical assays, one constant is that none 
of the catechol-containing compounds is cytotoxic, as judged by the results for the Vero cell assay, and, more importantly, for three of 
the four compounds, the biochemical activity correlates relatively well with the activity observed in the cell-based parasite growth 
inhibition assay, suggesting that the activity for these compounds is on-target. Ultimately, the compound high-lighted in this table (CID 
56846691) was nominated as the probe (and assigned the NIH Molecular Libraries Initiative probe number ML369), based on the good 
activity against rPfM18AAP, good selectivity against the rPfM1MAA and rPfM17LAP enzymes, and lack of cytotoxicity, even though 
the compound showed no selectivity against the rhM18. 
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Table 12. Probe Candidates (Catechol-containing Compounds Only) from Round 1 and 2 SAR. 
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Cellular Activity 
The malaria parasite in vitro growth inhibition assay and the Vero cell cytotoxicity assay are cell-
based assays. The majority of compounds screened were active in the malaria parasite killing assay 
and were inactive in the Vero cell cytotoxicity assay. The cellular permeability (PAMPA) for 
ML369 and three of the supporting analogues was measured and was determined to be good. The 
cellular permeability for the probe (PAMPA) was determined to be approximately 1400 × 10-6 
cm/s, 900 × 10-6 cm/s, and 120 × 10-6 cm/s at pH 7.4, 6.2, and 5.0, respectively.  
Profiling Assays 
The probe was submitted to Eurofins Panlabs for screening in the LeadProfilingScreen, a screen 
profiling binding to 68 protein targets of therapeutic or toxicological interest, and the results for 
this screen are listed in detail in Appendix H. In summary, not surprisingly, the probe was observed 
to be particularly active against a few of the GPCR biological targets, such as the dopamine 
transporter and norepinephrine transporter, for which it shares structural similarity to the known 
ligands, dopamine and norepinephrine, respectively. In addition, significant activity was observed 
against the hERG potassium channel. While the potential for GPCR and ion channel activity would 
be most important if the probe were recommended for use in in vivo studies, this activity is much 
less important with respect to the more limited recommended uses for ML369 (i.e., biochemical 
and cell-based assays; electron microscopy studies; biotin, photo-affinity, or fluorescent 
conjugates for chemical biology; co-crystallography with rPfM18AAP; modeling with 
PfM18AAP; and physical chemistry to study lysosomotropic properties). In any case, as the SAR 
surrounding ML369 is expanded to include bioisosteric replacements for the putative catechol 
zinc-binding domain, testing for off-target effects should include GPCR and ion channel targets. 
The probe compound and supporting analogues were submitted to the Sanford-Burnham Medical 
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Research Institute for various levels of in vitro pharmacology profiling (i.e., aqueous solubility in 
Pion's buffer (pH 5.0, 6.2, and 7.4), aqueous solubility in 1x PBS, cell permeability, (PAMPA), 
plasma stability (human and mouse), plasma protein binding (human and mouse), hepatic 
microsome stability (human and mouse), and toxicity towards Fa2N-4 immortalized human 
hepatocytes), and the results are provided in Table J1, Appendix J. Overall, the probe showed 
moderate aqueous solubility that increases as pH decreases, very good permeability that decreases 
as pH decreases, poor/very poor stability to human/mouse plasma, high binding to human/mouse 
plasma proteins, very poor/poor stability to human/mouse hepatic microsomes, and no significant 
toxicity toward immortalized human hepatocytes. See the Appendix D for the experimental 
procedures for the various in vitro PK measurements. 
Discussion 
At the outset, the aim of this project was to identify inhibitors of PfM18AAP that were selective 
versus PfM1MAA and PfM17LAP which also inhibited cell-based parasite growth and were also 
non-toxic to Vero cells. Subsequent to the HTS campaign, the previously unreported human 
recombinant M18 became available (Dalton Lab), and was incorporated into the list of anti-targets. 
After screening a compound library of almost 300,000 members and two subsequent rounds of 
SAR optimization, compound ML369 was identified, and, for the first time, a correlation between 
inactivation of the PfM18MAAP and malaria parasite killing was demonstrated. In general, the 
non-toxicity of this compound against mammalian cells augurs wells for the development of anti-
malaria drugs that do not exhibit toxic off-target effects, although this must be examined in vivo 
in the future. 
While the probe shows no selectivity against the human rM18, it also did not show toxicity against 
mammalian cells. The lack of toxicity against mammalian cells could suggest that the compound 
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is taken into parasite-infected RBCs via a mechanism that is not active in mammalian cells. It is 
well known that malaria parasites insert various transport channels into the membrane of the RBC, 
which facilitates the active up-take of nutrients and other compounds (e.g. amino acids) form the 
external milieu. 
The probe ML369 meets the probe criteria for the project, which are listed in the Table 13. 
Table 13. Comparison of the Observed Probe Properties to the Probe Criteria. 
 
Comparison to existing art and how the new probe is an improvement 
The prior art was investigated by searching the Chemical Abstracts database using the SciFinder 
software. Abstracts were obtained for all references returned from the search and were analyzed 
for relevance to the current project. For all references that were deemed relevant, the articles were 
analyzed and the results are summarized. These search results were current as of April 4, 2013. 
The only existing prior art was reported from the labs of the assay providers Dalton and Gardiner13. 
Dalton and Gardiner prepared phosphinic and phosphonic acid derivatives of aspartic and glutamic 
acid, the N-terminal acidic amino acids for which the specificity of the aspartyl aminopeptidase is 
restricted, for which the Ki's against rPfM18AAP ranged from a high of >2000 uM to a low of 
0.34 uM (Figure 14). While a number of these inhibitors showed moderate inhibition of 
rPfM18AAP, none of the inhibitors showed any significant inhibition of the growth of P. 
falciparum D10 parasites in culture (even at 100 uM final concentration). 
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Figure 14. Reported Inhibitors of rPfM18AAP which are analogues of the target amino acids 
Asp and Glu.. 
The selectivity for these compounds toward rPfM1MAA, rPfM17LAP, and rhM18, and their 
cytotoxicity against Vero cells was not reported. The current probe is in an improvement over this 
prior art, in that, it is the first small-molecule inhibitor for rPfM18AAP that is moderately selective 
against rPfM1MAA and rPfM17LAP and exhibits good blocking of parasite growth in culture (e.g. 
lower than the broad-range neutral aminopeptidase inhibitor bestatin, IC50 10 uM), and, strikingly, 
is not toxic to Vero cells. The studies support that PfM18AAP is a viable target for anti-malarial 
drug discovery as the studies suggest the first link between its enzymatic inhibition and parasite 
killing via small-molecule compounds. 
Mechanism of Action Studies 
The assays used in this project included a combination of on- and off-target biochemical and cell-
based assays. Recombinant PfM18AAP was used for the biochemical target assay, while 
recombinant FhCTSL1, PfM1MAA, PfM17LAP, and human M18 were used for the biochemical 
anti-target assays. Malaria parasite growth inhibition in red blood cells and cytotoxicity against 
Vero cells were used as the cell-based target and anti-target assays, respectively. While the probe 
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ML369 and a handful of analogues listed in Table 12 show activity across this suite of assays that 
is consistent with an on-target mechanism of action, some ambiguity does remain, in this regard. 
Future studies, including additional rounds of SAR, the measurement of IC50 values against the 
native PfM18AAP, PfM1MAA, and PfM17LAP, and activity-based protein profiling using 
derivatives of the current, or improved, probes could address this ambiguity. In addition, one could 
imagine performing an experiment to help clarify the mechanism of action, whereby, PfM18AAP 
is overexpressed in the cell-based assay, and if the probe and analogues are acting on target their 
activity might be reduced. 
Planned Future Studies 
SAR Studies 
Additional rounds of SAR could combine the structural features of the compounds listed in Table 
12. For example, the first and third compound structures or the first and fourth compound 
structures could be combined to afford the compounds on the left and right, respectively, in the 
Figure 15. 
 
Figure 15. Example Future SAR Studies. 
Bioisosteric replacements for the catechol moiety, such as those popularized by Cohen, should 
also be revisited 63. While many such catechol replacements were earmarked for synthesis, only a 
few were prepared due to the challenges associated with their preparation. 
Mechanism of Action Studies 
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The mechanism of action for the probe or analogues could be explored using affinity-based protein 
profiling. This chemical biology strategy using bestatin-based probes has been used to illuminate 
the distinct roles for malaria PfM1MAA and PfM17LAP73. While the activity for the current probe 
is at the upper-end of what might be considered useful for such a probe, ideally, additional SAR 
studies should lead to significantly more active analogues, with activities more appropriate for 
such studies. The SAR studies to date suggest that the region of the inhibitor structure that is distal 
to the catechol moiety is a likely candidate for conjugation to biotin, photo-affinity, or fluorescent 
labels. 
Co-Crystallization Studies using rPfM18AAP and the Probe or Analogues 
Recently, the 3-D structure of the malaria recombinant PfM18AAP was resolved and showed that 
the enzyme exists as a large complicated multimeric structure64. Because of the lack of availability 
of a potent inhibitor, no structure for an inhibitor-enzyme complex was obtained. However, the 
activity and solubility of the current probe, and its analogues, should now fill this gap. One of the 
probe analogues, in particular, CID 53308676 (Table 8, entry 3), that shows potency in the low 
single-digit micromolar range (IC50 against the rPfM18AAP) is quite soluble in aqueous solution 
across the pH range from 5.0 to 7.4 (>0.5 mM). Co-crystallization studies should allow a better 
understanding of the manner in which these compounds bind and interact with the malaria enzyme. 
Fluorescent and Electron Microscopy Studies 
Fluorescent and electron microscopy studies could be used to examine the capacity for the probe 
and analogues to disrupt the intracellular architecture of the malaria cell. For instance, as reported 
by Trenholme et al., one could envision the development of an assay utilizing a green fluorescent 
protein chimera of PfM18AAP as a marker for analysis of parasites via fluorescence activated cell 
sorting which would allow for the accurate assessment of PfM18AAP production and when 
 92 
changes are apparent within the malaria cell.14 
Studies on the Physical Properties of the Probe and Analogues and Their Selective 
Accumulation in the Parasitophorous Vacuole 
The uptake and intracellular distribution properties of a compound are fundamentally important 
variables in achieving a potent and desirable biological response. The ability of compounds to 
cross cellular lipid bilayers is a necessary step in this process but rarely is it a sufficient one. This 
is because cells are highly compartmentalized entities with over 50% of their total volume 
comprised of membrane-bound organelles/compartments that can provide barriers between a 
probe and its intended target molecule. 
Malaria parasite enzymes that interfere with hemoglobin digestion/metabolism are often presumed 
to be localized, at least partially, within the acidic digestive vacuole. Interestingly, PfM18AAP has 
been shown to be secreted into the parasitophorous space 13, which is also acidic due to the action 
of the V-H+-ATPase localized at the plasma membrane of the parasite 74. Being relatively acidic, 
these compartments have the propensity to significantly concentrate weakly basic compounds 
according to an ion trapping-type mechanism. Accordingly, we hypothesize that compounds that 
have ideal structural and physicochemical properties that promote ion trapping (i.e., 
lysosomotropism) will have enhanced interactions with PfM18AAP relative to non-
lysosomotropic counterparts. It is important to note that the presence or absence of lysosomotropic 
properties should not influence probe interactions with PfM18AAP in such assays. However, the 
lysosomotropic propensity of probes will be expected to favor interactions with PfM18AAP in the 
anti-malarial red blood cell cell-based assay since intracellular proton gradients are actively 
maintained. Interestingly, lysosomotropic compounds show enhanced potency in anti-malarial 
assays65. 
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For next-generation probe analogues we will rationally incorporate functional groups that will 
impart increasing degrees of lysosomotropic properties and evaluate them using in vitro enzyme 
inhibition and RBC-based anti-malarial assays as described, previously. There are two key 
physicochemical properties of drugs that influence the degree of ion trapping in acidified 
intracellular compartments that will be systematically modified. The first parameter is the pKa 
value of the conjugate acid of the weak base75. The second is the ratio of the permeabilities of the 
base in the ionized versus unionized form76. We will experimentally estimate the ratio of 
permeabilities by evaluating octanol/water partition coefficients as a function of pH as previously 
described76. The pKa values of probes will be estimated using spectrophotometric approaches. In 
addition, we will experimentally determine the lysosomotropic characteristics of the probes using 
a recently developed approach that has been validated using the fluorescent lysosomotropic probe 
Lysotracker Red (LTR). In this approach we comparatively evaluate the total cell uptake in cells 
before and after treatment with ionophores nigericin and monensin. The ionophores dissipate the 
lysosome-to-cytosol pH gradient that provides the driving force for ion trapping, and cells treated 
with ionophores have markedly reduced lysosomal sequestration of LTR. Using this data we can 
mathematically arrive at the percentage of total cell uptake that is driven by an ion trapping-based 
mechanism. For lysosomotropic molecules such as LTR, greater than 76% of its total cell uptake 
can be attributed to ion trapping. This measure of lysosomotropic potential will be evaluated for 
all probe analogues. Using these approaches, together with optimization of pKa and permeability 
ratios of probe analogues, we expect that next-generation probes will have greatly enhanced 
intracellular distribution properties and therefore fully optimized anti-malarial activity if the 
lysosomotropic hypothesis is correct. 
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Pros and Cons Ways of Improving Screening Methods for On-target Effects  
Again, while we identified a novel molecular probe ML369 that shows activity across this suite of 
assays that is consistent with an on-target mechanism of action, some ambiguity does remain, in 
this regard. It would be beneficial to screen initially against the native proteins PfM18AAP, 
PfM1MAA, and PfM17LAP. The difficulty in doing so is in the scalability in obtaining sufficient 
quantities of native enzyme which is a constant fundamental problem in large scale HTS which 
typically requires liters of material which aren’t always easy to obtain nor cost effective. Another 
approach which we could apply is an activity-based protein profiling methodology using 
derivatives of the current probe which could also help address this ambiguity. In this sense the 
probe, ML369, would be chemically conjugated to a fluorophore such as rhodamine and then 
applied either a gel based ABPP determination or fluorescence polarization readout. The 
complication in this approach is the labeled probe would increase the size of the current probe 
dramatically which may or may not decrease its potency.  
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Chapter 4 
Targeting Plasmodium falciparum Gametocytes 
 
Chapter 4 is directly derived from my manuscript demonstrating how I found compounds that 
inhibit the activity of Plasmodium falciparum Gametocytes by high-throughput screening. 
Please see Spicer, et.al.. Identification of Antimalarial Inhibitors Using Late-Stage Gametocytes 
in a Phenotypic Live/Dead Assay. SLAS Discovery.  2018 August. PMID:30142014.  (Appendix 
A).  
My contribution to the authorship includes a substantive contribution to the following activities: 
1) conception and design of the project as well as execution of the experiments; 
2) analysis and interpretation of the research data on which the publication is based; 
3) drafting the publication as well as completing its submission as the communicating author. 
 
Summary: 
According to the World Health Organization (WHO) the parasites responsible for causing human 
malaria, Plasmodium falciparum, P. vivax, P. ovale P. malariae and P. knowlesi infect up to 216 
million people per year resulting in an estimated 445,000 fatalities77. Current antimalarial regimens 
are not fully effective due to emerging drug resistance and their inability to prevent 
transmission17,78. Approximately 40% of the world’s population lives in areas where the risk of 
malaria transmission is high, typically the tropic zones located closer to the equator27. 
The WHO along with charitable organization such as Gates Foundation and the global ministries 
from highly affected countries, are now driving renewed efforts toward the eradication of malaria.  
While vector control strategies, including impregnated bed nets and drug therapies such as 
artemisinin combination therapies have helped tremendously their efficacy may have plateaued.  
Additionally, while at least one vaccine, Mosquirix or RTS,S exists, it appears to have limited 
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efficacy in inducing either robust antigenic responses or long-lasting immunity, thus leaving some 
vaccinated individuals unprotected. It remains under study to determine just how effective it 
is79,39,40. Vector control and case management by chemotherapy remain the primary means of 
control for malaria. In the best scenario, while we may be able to achieve low levels of infection, 
additional measures are still necessary for complete eradication. This is true, in part, because drug 
resistant parasite strains are evolving thus providing a reservoir for transmission80.  In other words, 
the route to complete elimination of malaria resides in our ability to not only block both the hepatic 
and erythrocytic stages of parasite replication within the human host but, also to block transmission 
or the parasite between the human host and the mosquito vector.   
Hence, we are focused on identifying inhibitors that act on this late-stage of the parasite’s lifecycle. 
Gametocytes are part of the sexual phase of the malaria parasite life cycle and are essential for 
transmission from one host to another via the mosquito. They are produced in the human host and 
once mature remain in a state of arrested cell development until ingested by a feeding female 
Anopheles mosquito where they undergo further development (Figure 16A)33,34.  
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Figure 16: (A) Lifecycle of Plasmodium falciparum. Gametocytes are transmitted to the 
mosquito vector during a blood feed. The point in the lifecycle where transmission-blocking 
therapies may be effective is annotated with the large red X. (1B) the five stages of gametocyte 
development of which this HTS effort targets stages IV and V. 
 
P. falciparum gametocytes require 10-12 days to reach maturity, passing through five distinct 
stages (I-V) along the way (Figure 16B)31. As the gametocytes mature to stage V they become 
relatively metabolically inert until they are taken up by a feeding mosquito33 and they can remain 
in the host circulation for significant periods of time at subpatent levels32. This lack of metabolic 
activity correlates to less druggable targets making them insensitive to almost all commonly used 
antimalarial agents and our own recent findings confirm and extend these results81,12. However, 
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some reports have found that late stage gametocytes have increased lipid requirements which is 
divergent from early stage asexual parasites making fatty acid metabolism a possible target82. Still, 
our group has confirmed that late-stage gametocytes (stage IV-V) are largely speaking, refractory 
to treatment by all the classes of antimalarial agents tested. This data indicates that even clinically 
effective antimalarial treatment of the host may not lead to the prevention of transmission. The 
metabolite of 8-aminoquinoline primaquine (PQ) is currently the only licensed antimalarial drug 
that is effective against late stage gametocytes83. Unfortunately, there are side effects to treatment 
with PQ which decrease its usefulness. It is also known to cause acute hemolysis in patients with 
G6PD deficiency, for whom PQ is contraindicated. G6PD deficiency is highly prevalent in malaria 
endemic areas and severely limits the use of PQ. Early reports that Tafenoquine has activity against 
gametocytes have not been confirmed and it appears to have no in vitro activity against stage IV/V 
gametocytes38. It too is contraindicated in patients with G6PD deficiency. Therefore, for both 
primaquine and tafenoquine, in vitro testing with the parent compound may not be a good guide 
to in vivo activity (for any parasite stage) as the metabolites generated by host enzymes, that are 
probably the anti-parasite active compounds, remain little understood. Therefore, blocking 
transmission of malaria by targeting late-stage gametocytes remains a top priority.  
Traditionally, HTS campaigns use one of two approaches to identify new agents against a given 
disease; cell based or target based. In contrast to the asexual stages, because late-stage gametocytes 
are essentially terminally differentiated, the effect of compounds on this stage cannot be monitored 
using cell multiplication as a marker. In addition, working with gametocytes is technically 
challenging and until very recently, methods for production of large numbers of gametocytes were 
not available14,49. Consequently, we have little information with respect to the differences in 
protein expression and metabolism between late-stage gametocytes and asexually replicating 
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parasites. As a result, neither a cell- or target-based HTS approach to identifying compounds with 
activity against gametocytes was feasible. However, as a result of improved gametocyte 
production methods and the development of tools for downstream analysis, by our group and 
others, large-scale anti-gametocidal HTS approaches are now feasible84,85,86. 
Herein, I describe the miniaturization and completion of a large-scale screening agenda using a 
phenotypic approach incorporating a live/dead assay which monitors ATP, and, hence, metabolic 
activity of gametocytes. Late-stage gametocytes were used in a rapid, cost effective, highly 
sensitive luminescent detection assay in 1536-well format for detection of phenotypic gametocyte 
inhibitors. I also report the results of a mammalian cell cytotoxicity assay which was employed as 
a counterscreen. 
Methodology: 
BacTiter-Glo microbial cell viability assay detection reagents were purchased from Promega 
Corp., Madison Wisconsin, and Part # G8231. The BacTiter-Glo microbial cell viability assay 
detection reagents detect the amount of ATP present in a live gametocyte. Therefore if a 
gametocyte is alive and metabolically active it will produce ATP which when detected using 
BacTiter-Glo, will result in a high luminescence signal. When a gametocyte is killed or becomes 
metabolically inactive then ATP is rapidly degraded and results in a massively reduced or low 
luminescence signal. This assay is designed to identify inhibitors of whole gametocyte activity and 
hence we are trying to identify compounds that achieve a low overall luminescence signal 
compared to vehicle treated wells.  Late-stage (Stage V) gametocytes were isolated and 
cryopreserved as previously described.14 These were subsequently shipped by overnight courier 
frozen on dry ice, to TSRI Florida where they were stored at -130 °C until the time of use. 
Cryopreserved gametocytes were thawed and returned to culture via a dropwise saline solution 
revitalization procedure followed by resuspension at 62,500 gametocytes per milliliter in RPMI 
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1640 (Life Technologies, 15750) supplemented with 10% human serum (BioWorld, 30611043-1), 
0.2% sodium bicarbonate and 10ug/ml of gentamycin (Life Technologies, 15750). Four microliters 
of gametocyte cell suspension were then dispensed into each well of 1536-well microtiter plates 
(250 cells per well) (Corning, part 7254) using the Flying Reagent Dispenser (FRD-Aurora 
Biosciences Corp). Next, 44 nanoliters of test compound in DMSO, low control (DMSO alone, 
1.08% final concentration) or high control (media only, no gametocytes) were added to the 
appropriate wells using the GNF pintool (GNF Systems). Low controls in this sense are “vehicle 
only” treated wells and will elicit an uninhibited luminescence response equivalent to the amount 
of viable gametocytes within the well whereas high control wells have no gametocytes and elicit 
no appreciable luminescence which is anticipated to be corollary to a compound with maximal 
inhibitory effect.  Plates were incubated for 24 hours at 37 °C, 95% relative humidity and 5% CO2, 
whereupon 4 microliters of BacTiter-Glo solution was added to all wells. Plates were centrifuged 
at 1000 RPM for 1 minute and luminescence was measured using a 30-second read on the ViewLux 
microplate reader (PerkinElmer Lifesciences). 
Compounds.   
The Molecular Libraries Small Molecule Repository library was provided by the NIH’s Molecular 
Libraries Initiative. Details regarding compound selection for this library can be found online 
(http://mli.nih.gov/mli/compound-repository/mlsmr-compounds/).  Briefly, the MLSMR library is 
a highly diversified collection of small molecules (more than 50% of compounds exhibit molecular 
weights between 350 and 410 grams per mole) comprising both synthetic and natural products, 
from either commercial or academic sources, that can be grouped into the three following 
categories: specialty sets of known bioactive compounds such as drugs and toxins, focused 
libraries aimed at specific target classes, and diversity sets covering a large area of chemical space. 
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Solid samples (powders) were purchased by the University of Kansas Specialized Screening 
Center from various commercial sources. Purity of all final compounds was confirmed by RP 
HPLC/MS analysis and determined to be > 95%. 1H and 13C NMR spectra were recorded on a 
Bruker AM 400 spectrometer (operating at 400 and 101 MHz, respectively) or a Bruker AVIII 
spectrometer (operating at 500 and 126 MHz, respectively). NMR spectra for the 13 purchased 
compounds used in the structure-activity relationship (SAR) analysis are shown in the 
supplemental materials. 
 
Data acquisition and analysis  
All screening assays were run on a Kalypsys/GNF robotic platform in 1,536-well microtiter plates. 
Luminescence was measured by the ViewLux plate reader using a luminescence protocol that 
utilized a 30 seconds exposure time.  Raw data were uploaded into an institutional HTS database 
(Symyx Technologies, Santa Clara, CA) for further processing.  Activity of each well was 
normalized on a per-plate basis using the following equation: 
The percent inhibition of each test compound was calculated as follows: 
% Inhibition= 100 *((Test Compound- Median Low Control))/ ((Median High Control- Median 
Low Control))  
Where: 
Test Compound is defined as wells treated with test compound. Low Control is defined as wells 
treated with DMSO only. High Control is defined as wells treated with media only and no 
gametocytes. 
Each assay plate underwent a quality control check; a Z’ value greater than 0.5 was required for 
acceptance of data87.  Any assay plate for which the Z’ value did not exceed 0.5 was rescheduled 
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for another robotic procedure until an acceptable Z’ value was observed.  
A mathematical algorithm was used to determine nominally inhibiting compounds in the primary 
screen. Percent inhibition is calculated for each individual well including control wells using the 
expression included above and applied here to determine an interval-based cut-off which was 
applied to take into account assay noise and general variability within compound activity to help 
preserve and identify more hits at the primary HTS phase88. Four values were calculated: (1) the 
average percent inhibition of all high controls tested plus three times the standard deviation of the 
high controls, (2) the average percent inhibition of all low controls tested minus three times the 
standard deviation of the low controls, (3) the average percent inhibition of all compounds tested 
between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, 
(3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % 
inhibition/activity than the cutoff parameter was declared active. 
For titration experiments, triplicate percent inhibition values were plotted against compound 
concentration. A four-parameter equation describing a sigmoidal concentration-response curve 
was then fitted with adjustable baseline using Assay Explorer software (Symyx). Concentration-
response curves and IC50 values presented in this manuscript were generated by Prism (GraphPad 
Software, San Diego, CA). In cases where the highest concentration tested did not result in greater 
than 50% inhibition, the IC50 was determined manually as greater than the highest concentration. 
Compounds with an IC50 greater than 10 uM were considered inactive. Compounds with an IC50 
equal to or less than 10 uM were considered active. 
Counterscreen 
The purpose of this cell-based assay is to determine if compounds that originally were found to 
inhibit viability of late stage P. falciparum gametocyte in a primary HTS assay, also are cytotoxic 
 103 
to mammalian cells, an undesirable feature. In the past, counterscreening utilizing this method 
when screening for other parasite targets has been extremely helpful in ruling out non-specific 
cytotoxic compounds, and, hence we sought to apply the same principle here24. 
This assay employs Jurkat cells, a human T-cell line originally isolated from an adolescent male 
with T cell leukemia. The cells are grown in suspension which facilitates tissue culture and 
preparation for dispensing in the assay. The end-point assay presented here employed a similar 
reagent to the primary assay, CellTiter-Glo luminescent reagent (Promega Corp. Part G7573), 
which contains luciferase enzyme to catalyze the oxidation of beetle luciferin to oxyluciferin and 
light in the presence of ATP, in this case from Jurkat cells. Since metabolically active cells produce 
ATP, an increase in the number of dead or dying cells will correlate with a reduction in ATP levels. 
As designed, compounds that inhibit cell viability and reduce intracellular ATP will reduce the 
catalytic conversion of luciferin into oxyluciferin, resulting in decreased luciferase activity and 
well luminescence. This assay included doxorubicin as a positive control, an antibiotic used as an 
anti-cancer drug which elicits an appropriate anti-proliferative effect on Jurkat cells.25 
Compounds are tested in triplicate using a 10-point 1:3 dilution series starting at a maximum 
nominal test concentration of 83.3 uM. 
Jurkat cells (clone E6.1; ATCC Cat# TIB-152) were routinely cultured in suspension in T-175 
standing flasks at 37 0C in 95% relative humidity (RH) at 5% CO2. Media consisted of RPMI-1640 
containing 10% dialyzed fetal bovine serum, 0.1 mM NEAA, 1 mM Sodium Pyruvate, 25 mM 
HEPES, 5 mM L Glutamine, and 1x antibiotic. 
Prior to the start of the assay, cells were suspended to a concentration of 100,000 cells/ml in media. 
To start the assay, 5 microliters of media was dispensed into the first two columns of a 1536 well 
plate and 5 microliters of cell suspension was dispensed to the remaining wells (500 cells per well). 
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The assay was started immediately by dispensing 42 nanoliters of test compound in DMSO, 
Doxorubicin (8 uM final concentration) or DMSO alone (0.6% final concentration) to the 
appropriate wells. The plates were then incubated for 48 hours at 37 0C, 5% CO2 and 95% RH). 
Following the two-day incubation, plates were equilibrated to room temperature for 10 minutes 
and 5 microliters of CellTiter-Glo reagent was added to each well. Plates were centrifuged and 
incubated at room temperature for 10 minutes. Well luminescence was measured on the ViewLux 
plate reader. The percent inhibition for each compound was calculated exactly as it was for the 
primary HTS assay using the following controls: Test Compound is defined as wells containing 
test compound, Low Control is defined as wells containing DMSO only (0% inhibition), and High 
Control is defined as wells containing 8 uM doxorubicin (100% inhibition). 
 
Results 
Since all HTS at Scripps is done in 1536-well format the  former 96-well method was further 
miniaturized to optimize conditions based on Z’ value and reproducible response to methylene 
blue, a known inhibitor of malaria (Table 14)12, 89.  The purpose of the methylene blue titration in 
this assay is to control for the day to day response of a known pharmacologic inhibitor of 
gametocyte viability. In a good whole cell based HTS campaign an IC50 value for a well validated 
control should not vary by more than two to three fold. In this case the value achieved was well 
within this tolerance at an average calculated IC50 of 14.7±6.6 uM. 
Table 14. Stepwise Protocol for the 1536-Well Plate Live/Dead Gametocyte Assay  
Order Step Condition Comments 
1 
Thaw frozen stock 
Revitalization of 
late-stage 
gametocytes 
Dilute to 62,500 gametocytes per milliliter in RPMI 1640 supplemented 
with 10% human serum, 0.2% sodium bicarbonate and 10ug/ml of 
gentamycin 
2 Dispense gametocytes 4μL/well 250 cells/well into 1536-well plates (Corning, part 7254) 
3 Pin compounds/controls 44nL Compounds pinned at ~10µM final concentration in ~1% DMSO 
4 Incubation 24 hours 37 °C, 95% relative humidity and 5% CO2 
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bDue to the novelty of this target, compounds with any observable activity in the Concentration-
Response assay, and not in the counterscreen, were of interest for follow-up. 
 
In particular, the number of gametocytes necessary per well to remain in the linear range of the 
detection modality was optimized, as was the incubation time, and further validated for HTS in 
the context of the  fully automated screening system. This resulted in using 250 gametocytes per 
well at >90% viability, immediately adding test compound in 75:25 DMSO:H2O, and incubating 
for 24hrs prior to adding BacTiter-Glo luminescence detection reagent. These conditions led to 
reproducible Z’ factor averaging 0.53±0.1 over the course of 124 assay test plates.  After testing 
>153,000 compounds at ~11 uM, 100 actives were identified using a cut-off set at >38% inhibition 
(Figure 17).
5 Dispense BacTiter-Glo 4µl/well Luminescence substrate is stable at RT 
6 Incubation 10 minutes 
RT incubation allows for plates to equilibrate to alleviate temperature 
gradient prior to reading 
7 
Read Luminescence 
Plates were centrifuged and luminescence was measured on aViewLux 
microplate reader (PerkinElmer, Turku, Finland) using a luminscence 
protocol that utilized a 30 seconds exposure time 
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Figure 17: (A) Scatterplot of the data from the primary HTS campaign. Wells were treated with either test compounds (black), no 
gametocytes (high control=red) or gametocytes only (low control=green). The hit cutoff is shown as an orange line at 38% inhibition. 
Titration results of the known anti-gametocyte cytotoxic compound methylene blue, N=4 separate experiments, N=16 wells per replicate 
point, error bars are shown. The average calculated IC50 was 14.7±6.6 uM.
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This effectively sets the hit cut-off such that it approaches the level of the sample field. Still, the 
hit rate was very low, observed as 0.1% of the compounds. This is further reflected by the average 
Z score assessed over the same course of plates equal to 0.60±0.05. Here Z factor is calculated 
using the method to generate Z’ but incorporates the use of the sample field in the expression used 
in place of the low controls. As such, achieving lower Z scores, such as those <0.5, would represent 
higher activity of the samples tested, which isn’t the case here.  
 
Considering the low number of actives identified, the project proceeded immediately to the 
concentration-response curve (CRC) determination phase, avoiding the expenditure of time and 
cost associated with the typical confirmation and counterscreen phase. Since this biological target 
is of major significance, difficult to hit, and the NIH repository allowed for up to 275 compounds 
to proceed to CRCs the hit list was expanded to include the top 275 molecules for testing. Of those, 
244 were available and subsequently tested in both the primary assay and counterscreen assay for 
CRC determination. Of the 244 molecules, only two compounds were identified with moderate 
potency and selectivity (see Table 15).  
Table 15: Summary of the Ultra-HTS campaign to Identify Inhibitors of Late Stage 
Plasmodium falciparum Gametocytes 
 
These two molecules, SR-01000751192 and SR-01000471307 were found to have potencies <10 
uM in the whole gametocyte assay (Figure 18). 
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Figure 18: Structure-activity relationship of the top active molecules identified as hits in this HTS campaign. Compounds are ranked 
with most potent first. Data has been normalized to “no gametocytes” as 100% inhibition vs. “DMSO and gametocytes” only. Data is 
plotted as log M on the x-axis versus percent inhibition on the Y-axis.  
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Only SR-01000751192 exhibited minimal cytotoxicity when tested in the Jurkat T-cell toxicity 
assay (>83 uM), an example of an HTS qualified assay for cytotoxicity profiling15.  
After validation of the hit compounds from dry powders that were originally identified from the 
high-throughput screening conditions and prior to moving into serious SAR optimization where 
analogs are typically obtained via laboratory synthesis, a routine procedure of analog-by-catalog 
(ABC) is usually performed to streamline the process. In this step, structurally close analogs are 
purchased from different commercially available sources that provide a basic idea to map the 
structural changes and their correlate with inhibitory activities. Often, this process provides useful 
insights towards which directions the structural changes should be performed to improve the 
potency before the onset of SAR optimization using synthetic efforts. In this project, a quick ABC 
process was carried out by purchasing analogs that are close structural analogs of the hit compound 
SR-01000751192 with single-, double-, and triple-point changes (as summarized in the attached 
files). Note that SR-01000751192 provided batch-to-batch reproducibility as identified from 
samples from the solid physical state. A raw 4 parameter curve fit for this compound yield nearly 
identical IC50 values (7.1uM -batch2 vs. 8 uM-original hit). A small set of analogs were obtained 
as fresh samples from the solid physical state. The late-stage SAR assay performed well with Z’ 
values averaging better than 0.6, and the methylene blue control worked as expected. The 
counterscreen assay also behaved as expected, with consistent Z’ scores, and response to the 
control doxorubicin. Unfortunately, improved anti-gametocydial activity was not observed for any 
of the 13 compounds purchased for initial SAR, although the compound sample from the solid 
physical state for the original compound hit did recapitulate the activity observed previously (see 
supplemental Table 1). Therefore, it is possible to conclude that changing with pyridyl substituent 
at the position 3 of the pyrazole with phenyl, substituted phenyl, and cyclopropyl groups led to 
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diminished activities. It was also observed that changing the thiazolyl structure by adding 
substituents, or additional heteroatom wasn’t tolerated.  
Outcomes- Targeting Plasmodium falciparum Gametocytes 
 
This work represents the first report of a large-scale HTS campaign completed in 1536 well format 
against late-stage P. falciparum gametocytes. Most HTS efforts targeting P. falciparum are 
directed at the liver and blood stages of the parasite life cycle (Figure 16). Some involve target 
based approaches such as isolation of purified proteins and screening for protease inhibitors that 
may block the active site for its respective substrate.8, 9 Others that have the potential to identify 
transmission blocking molecule are low throughput and or non-homogenous in assay format 
making them ill-suited for large scale HTS.86  As a critical biological target of unmet therapeutic 
need, the bar was set low in terms of accepting any compound hit of appreciable activity to proceed 
for further testing. This meant incorporating a conservative primary HTS cut-off followed by a 
rather relaxed 10 uM IC50 cut-off in the late-stage analysis. While our efforts were in progress, a 
few key hurdles were overcome. During the HTS of the gametocyte project there was an 
unavoidable but, significant batch-to-batch difference in the gametocyte numbers and viability 
which was overcome by pooling the batches at the point of HTS testing. This afforded an assay 
with acceptable Z’ scores. Methylene blue, while not a good anti-malarial drug due to side effects 
in humans90, was used as a pintool-transferred control on each plate and was also tested for anti-
gametocidal pharmacologic response as a CRC control during each experiment and during each 
run. It is notable that the Z and Z’ values are nearly overlapping, which simply indicates the overall 
activity of the test compound was very low. The initial hits, while low in efficacy, do consistently 
reproduce activity in both labs (Scripps and QIMR Berghofer Medical Research Institute 
(QIMRB). While it is unusual to obtain such a low hit rate against such a large number of diverse 
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compounds tested, namely the Molecular Library Probe Production Centers Network (MLPCN) 
library which has yielded multiple clinical drugs,91 this observation highlights the complexity and 
natural resistance, or refractiveness, of the gametocytes to the cytotoxic effects of small molecules, 
similar to what has been observed by others to date. Incorporating a cytotoxicity counterscreen 
was effective in focusing attention on SR-01000751192 and SR-01000599986, but with the limited 
hit set may not be as useful at this stage as originally planned. Ultimately, the HTS campaign was 
successfully completed against this difficult target and there were no insurmountable challenges 
encountered. 
This work involved a multi-institute and multi-content initiative that was supported by the 
MLPCN.  One of the mains goals of the MLPCN was to identify novel molecular probes; i.e. 
ligands that supersede the activity of all prior art in all assays of relevance to support such an 
achievement. So the goal was to obtain a series of small molecules that met these criteria. Based 
on this outcome, a probe was not identified for this project which would have been defined as a 
compound the elicited an anti-gametocidal effect < 500nM IC50 versus the primary assays and 
which produced reasonable potency in the low-throughput mechanism-of-action assays, such as 
the in vitro  assay performed at QIMRB.  
An alternative approach that has shown promise by others incorporated fragment based screening 
against biochemical targets in tandem with phenotypic assays92,93. Perhaps, armed with a 
biochemical assay directly targeting gametocytes, this hybrid approach would have helped here 
but, at the time of writing none such exist that are HTS amenable. It can be concluded that this 
method of HTS provides a path forward for future HTS, perhaps testing larger more diverse 
libraries for anti-gametocidal inhibitor identification and development. 
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Chapter 5 
Conclusion of Thesis  
 
 
Progress toward the original aims 
• I have adapted, implemented, optimized and developed each target into robust HTS 
amenable assays including their respective confirmation and counter screens.  
• I completed large scale compound screening (>150K compounds) on diversified molecular 
collections for each target using a fully automated robotic screening system followed by 
secondary analysis and subsequently concentration response analysis of the most 
promising HTS hits including testing in late stage specificity assays. 
• At the conclusion of the HTS campaigns I took lead like molecules through early medicinal 
chemistry efforts and in the case of the rPfM18AAP developed and submitted novel 
molecular probes to the NIH via the PubChem database which can be found at 
http://www.ncbi.nlm.nih.gov/books/NBK179825/ (ID: 3070092) and represents a 4.6nM 
effective inhibitor of this target with >16X selectivity over the anti-target rPfM1MAA. 
• Finally I drafted, submitted and obtained publications in a peer reviewed journal that is 
germane to HTS for the PfM18AAP effort and also the gametocyte. Both are published in 
SLAS Discovery.  
Problems encountered 
During the course of this work the biggest issue was with the gametocyte effort directly related to 
the scalability of the assay. This required multiple batches of late stage whole cell live gametocytes 
to be prepared in Australia and delivered to Scripps in the USA. This required each batch to be 
 113 
tested separately, for appropriate efficacy, and subsequently pooled during the HTS effort in order 
to produce sufficient S:B and Z’. While adding an unexpected burden it was ultimately successful.  
Final Outcome 
At the conclusion of my thesis work the original goals of this work were all well achieved.  A good 
example is shown in the outcomes of the PfM18AAP HTS campaign which resulted in two 
publications and the identification of a novel molecular probe inhibitor proving for the first time 
this protein can be targeted for small molecule drug discovery. 
The large scale screen against the whole cell late stage gametocytes was also successful which, 
identified reproducible activity of the best inhibitors through medicinal chemistry, both of which 
had never before been done on such scale nor in a 1536 well HTS. This work also resulted in a 
third publication accepted in the foremost leading journal for the publication of HTS results.  
However, not all the work went easily. In this sense the gametocyte scalability was the biggest 
concern. Scalability of cells in HTS is always a primary consideration and can be daunting if not 
well planned. Gametocytes fall into this category. To achieve the proper number of gametocytes 
required production of multiple batches of late stage whole cell live gametocytes to be prepared in 
Australia and delivered to Scripps in the USA. In HTS, like other areas of science, reproducibility 
of the day to day results is paramount. Typically I use one batch or pooled batch of cells to achieve 
the robustness and reproducibility required. Hence each batch of gametocytes had to be tested 
separately, for appropriate efficacy, followed by subsequently pooling during the HTS effort in 
order to produce sufficient S:B and Z’. This work encumbered multiple shipments and hundreds 
of vials of gametocytes produced from dozens of batches. All told this was a bit of an unexpected 
burden but ultimately I was successful.  
Malaria research has clearly benefitted from the work presented in my thesis albeit there is much 
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more that must be done in order to create effective cures. Funding remains the primary hurdle for 
future work to proceed.  My greatest need in this regard would be to be able to fund and further 
investigate more compounds to find better starting points for medicinal chemistry initiatives 
targeting gametocytes.  Leveraging HTS in this sense was limited to testing only 150K compounds 
but, if I could interrogate the Scripps Drug Discovery library in its entirety that would include 
665K molecules never before tested in the whole cell gametocyte assay. An effort of this 
magnitude would be costly and still presents significant risk but it would afford us new 
opportunities and directions to go in. 
Alternative approaches targeting the transmission of malaria via anti-gametocidals have more 
recently focused on distinguishing male and female gametocyte formation using sensitive reports 
to help identify which a small molecule is targeting which is perceived to help understand the 
transmission blocking capabilities of such molecules. This approach combined with the suite of 
assays including some of those described in this thesis may ultimately lead investigators to the 
next generation of anti-malarial inhibitors and perhaps even block transmission which would 
lead to a cure94,95. 
So in conclusion, my thesis work has advanced significant findings towards filling gaps in public 
health and knowledge related to early drug discovery directed at malaria. Prior to this work no 
one had successfully completed large scale screening on neither PfM18AAP nor whole cell 
gametocytes. The peer reviewed publication and probe report detailing the identification of the 
initial hit and subsequent chemical optimization and characterization of ML369 has at a 
minimum provided the field with a molecular control for future drug discovery efforts. In 
addition this has provided a well planned and executable road map for anti-malarial assay 
development, optimized and miniaturized HTS, post HTS medicinal chemistry support, and 
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small molecule lead development. It also provides the starting point and chemical basis for 
others to refine their own work towards lead identification and potential drug development. 
Finally, while a chemical probe was not identified for the anti-gametocidal effort,  it did shine a 
spotlight on how to pursue early drug discovery related to preventing malaria transmission; 
something that both the NIH and the world sees as a critical goal and unmet need which if 
effective will save millions of lives in a very short period of time. It also clearly provides proof 
of principal for screening and early drug discovery against a very tricky, finicky target. This has 
affected the malarial research community in numerous ways in that we now know that the hit 
rate and ability to kill whole cell gametocytes is not trivial but, possible.  Future work by our 
group will included more whole cell gametocyte screening against a diversified chemical library 
such as the Scripps Drug Discovery Library. This library is unique from the library I screened 
(MLPCN NIH library) and has been shown to be < than 15% overlapping.  Finally, this 
innovative work has been exploited at the international level in which others have used the exact 
same methods to screen their small molecule; a major accomplishment in its own right.  
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ABSTRACT 
The target of this study, the PfM18 aspartyl aminopeptidase (PfM18AAP), is the only AAP present 
in the genome of the malaria parasite Plasmodium falciparum. PfM18AAP is a metallo-
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exopeptidase that exclusively cleaves N-terminal acidic amino acids glutamate and aspartate. It is 
expressed in parasite cytoplasm and may function in concert with other aminopeptidases in protein 
degradation, of, for example, hemoglobin. Previous antisense knockdown experiments identified 
a lethal phenotype associated with PfM18AAP suggesting that it is a valid target for new anti-
malaria therapies. To identify inhibitors of PfM18AAP function, a fluorescence enzymatic assay 
was developed using recombinant PfM18AAP enzyme and a fluorogenic peptide substrate (H-
Glu-NHMec). This was screened against the Molecular Libraries Probe Production Centers 
Network (MLPCN) collection of ~292,000 compounds (the Molecular Libraries Small Molecule 
Repository (MLSMR)). A Cathepsin L1 (CTSL1) enzyme-based assay was developed and used as 
a counterscreen to identify compounds with nonspecific activity. Enzymology and phenotypic 
assays were used to determine mechanism of action and efficacy of selective and potent 
compounds identified from HTS. Two structurally related compounds, CID 6852389 and CID 
23724194, yield uM potency and are inactive in CTSL1 titration experiments (IC50 >59.6 µM). As 
measured by Ki assay, both compounds demonstrate uM non-competitive inhibition in the 
rPfM18AAP enzyme assay. Both CID 6852389 and CID 23724194 demonstrate potency in 
malaria growth assays (IC50 4 µM and 1.3 µM, respectively).  
Key words: Malaria, Plasmodium falciparum, Aspartyl aminopeptidase, PfM18AAP, parasite, 
exopeptidase, 1536 well, QFRET 
 
INTRODUCTION 
According to the World Health Organization (WHO) the parasites responsible for causing malaria, 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae infect 
up to 500 million people per year and result in an estimated 650,000 fatalities 77. Current 
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antimalarial regimens are not fully effective due to emerging drug resistance and lack of their 
ability to prevent transmission (2). Approximately 40% of the world’s populations live in areas 
where the risk of malaria transmission is high, typically the tropic zones located closer to the 
equator. The symptoms of malaria have a rapid onset with recurrent cycles of fever and chills, 
muscle aches, headaches, vomiting and jaundice, but may be extended to 8-10 months after the 
initial infected mosquito bite occurs (3).   
The life cycle of Plasmodium falciparum, the most prevalent and severest etiologic agent of 
malaria, is complex. It is transmitted by the female Anopheles mosquito to its human host where 
the parasites first enter the liver cells before emerging and invading erythrocytes. It is during this 
stage that P. falciparum utilizes protein-protein interactions and enzymatically-driven processes 
to allow entry, growth and escape from the human erythrocyte. One such enzyme is PfM18AAP, 
a ~67kDa metallo-aminoipeptidase that oligomerizes and is the sole aspartyl aminopeptidase 
(AAP) present in the malaria parasite (4). PfM18AAP is thought to play an important role in the 
process of protein degradation, and working together with other exo-aminopeptidases is believed 
to digest host hemoglobin, an important source of amino acids for the parasite (5,6). PfM18AAP 
may also interact with the erythrocyte membrane protein, spectrin, presumably to regulate the 
integrity of the infected erythrocyte membrane skeleton during parasite growth allowing for host 
cell expansion and parasite exit 96. Antisense RNA knockdown experiments have shown that 
inhibition of intra erythrocytic PfM18AAP debilitates the malaria parasite making it a promising 
drug target (6). Inhibitors of PfM18AAP will thus provide new tools to further our understanding 
this enzyme’s function and increase the potential to develop therapies against P. falciparum 
transmission.  
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Currently there are no known small molecule inhibitors of PfM18AAP.  Previous reports have 
identified the phosphinic and phosphonic acid analogs of glutamate and aspartate, GluP and AspP, 
as modest amino-acid-derived inhibitors of PfM18AAP in vitro.  However, these amino acid 
derivatives do not reduce malaria growth in culture when tested at concentrations up to 100 µM 
13. Thus the objective of this research program was to identify compounds that inhibit the activity 
of rPfM18AAP. Described here is our approach to discovering such inhibitors by an HTS of 
compound libraries, which yielded several series of potent compounds that demonstrate selectivity 
to the enzyme. Two of these compounds are non-competitive inhibitors of rPfM18AAP and also 
inhibit growth of P. falciparum. 
 
MATERIALS AND METHODS 
Recombinant enzymes and assay reagents. Functionally active purified recombinant PfM18AAP 
was prepared at University of Technology Sydney as previously described (8). Characterization 
studies with this enzyme have demonstrated that it has comparable properties to that of native 
PfM18AAP taken from cytosolic extracts (8). Recombinant cathepsin L was prepared in the same 
laboratory as previously described 97. All other reagents were purchased or made from standard 
laboratory supplies as listed: H-Glu-NHMec substrate (Bachem, part I-1180); Z-Leu-Arg-MCA 
substrate (Peptides International, part MCA-3210-v); 1,536-well plates (Greiner, part 789176); 
Tris (Amresco, part 0497); CoCl2.6H20 (Univar, part D3247); DTT (Invitrogen, part 15508-013); 
ZnCl2 (Sigma, part 208086); Z-Phe-Ala-diazomethylketone (Bachem, part N-1040); BSA 
(Calbiochem, part 126609). rPfM18AAP assay buffer was prepared as 50 mM Tris HCl pH=7.5, 
4mM CoCl2, 0.1% BSA (w/v). rPfM18AAP substrate buffer was prepared as 50 mM Tris HCl pH 
8.8. CTSL1 assay buffer was prepared as 25mM Tris HCl pH 7.5, 1 mM DTT, 0.1% BSA (w/v). 
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Compounds.  The Molecular Libraries Small Molecule Repository library was provided by the 
NIH’s Molecular Libraries Initiative. Details regarding compound selection for this library can be 
found online (http://mli.nih.gov/mli/compound-repository/mlsmr-compounds/).  Briefly, the 
MLSMR library is a highly diversified collection of small molecules (more than 50% of 
compounds exhibit molecular weights between 350 and 410 g/mol) comprising both synthetic and 
natural products, from either commercial or academic sources, that can be grouped into the three 
following categories: specialty sets of know bioactive compounds such as drugs and toxins, 
focused libraries aimed at specific target classes, and diversity sets covering a large area of 
chemical space. Solid samples (powders) of CID 6852389 (SID 11532952/87693049) and CID 
23724194 (SID 47200698/92117383) were purchased from Sigma Chemical Company (Catalog # 
D043) and Vitas-M Laboratory (Catalog # STK091533), respectively.  
rPfM18AAP screening assay. This enzymatic assay utilizes a fluorogenic peptide substrate (H-
Glu-NHMec), which is incubated with purified recombinant PfM18AAP in the presence of test 
compounds. Cleavage of the substrate by PfM18AAP liberates the 7-amino-4-methylcoumarin 
fluorogenic leaving group (NHMec) from the peptide, leading to increased fluorescence (Figure 
1).  Enzymatic inhibitors block rPfM18AAP-mediated cleavage of H-Glu-NHMec and liberation 
of the NHMec leaving group from the substrate, resulting in decreased fluorescence as measured 
at 340 nm excitation and 450 nm emission.  In order to reduce the number of compounds that 
optically interfere with the measurement, initial (T0) and 90 minute (T90) measurements of plate 
fluorescence were taken after addition of substrate. Test compounds were assayed in singlicate at 
a final nominal concentration of 7 µM. A stepwise assay protocol is presented in Supplemental 
Table 1. Further details of this assay can be found at the PubChem AID 1822 
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(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1822). The performance of the assay at 
various stages of the HTS campaign is listed in Table 1.  
Cathepsin L1 (CTSL1) screening assay. CTSL1 is a functionally active recombinant form of a 
cysteine endopeptidase derived from the worm parasite Fasciola hepatica. Similar in principle to 
the rPfM18AAP assay, this enzymatic assay utilizes a fluorogenic peptide substrate (Z-Leu-Arg-
NHMec) that is incubated with purified recombinant CTSL1 in the presence of test compound. 
This assay serves as a useful counterscreen because it also measures the level of the released 
coumarin moiety to monitor enzyme activity, albeit using a completely different enzyme. Hence, 
compounds that inhibit both assays are either non-specifically inhibiting the enzymes or possibly 
behaving as fluorescence quenching artifacts. Either outcome is undesirable and leads to a 
definitive path to remove unwanted compounds. Final assay conditions are shown in 
Supplemental Table 1. Methods for data analysis and hit selection were identical to those used 
for the rPfM18AAP HTS assay. This biochemical assay served as the counterscreen for each step 
of the rPfM18AAP HTS campaign; compounds that were active against this target and 
rPfM18AAP were not pursued at subsequent HTS campaign stages (Table 1). 
rPfM18AAP HTS campaign. Details relative to each step of the rPfM18AAP & CTSL1 screening 
assays are shown Table 1. Briefly, the first stage involved singlicate screening against PfM18AAP 
(the primary screen) and CTSL1 (the primary counterscreen) at a final compound test 
concentration of 7 µM or 6 µM, respectively (see PubChem AIDs 1822 and 1906 for protocol 
details).  The final DMSO concentration was 0.7% (v/v) for the PfM18AAP assay or 0.6% for the 
CTSL1 assay. Well fluorescence was measured with a ViewLux plate reader (Perkin Elmer), and 
the percent inhibition of each test compound was calculated on a per-plate basis as further 
described below.  The numerical cutoff used to qualify active (“hit”) compounds was calculated 
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as the average percentage inhibition of all compounds tested plus three times their standard 
deviation (10). The confirmation and counter screens were run on selected hits in the same 
conditions as the primary screens, except that plates were assessed in triplicate and results for each 
compound were reported as the average percentage inhibition of the three measurements, plus or 
minus the associated standard deviation (PubChem AIDs 2170 and 2178). For titration 
experiments, assay protocols were identical to those described above, with the exception that 
compounds were prepared in 10 point, 1:3 serial dilutions starting at a nominal test concentration 
of 74 µM, and assessed in triplicate (PubChem AIDs 2195 and 2196).  To confirm activity of the 
best inhibitors, compounds were purchased as powders samples and tested in various secondary 
assays including Ki determination and two other assays including a malaria cell lysate assay and a 
P. falciparum parasite growth assay (see below). 
Screening data acquisition, normalization, representation and analysis. All screening assays 
were run on a Kalypsys/GNF robotic platform in 1,536-well microtiter plates. Fluorescence was 
measured by ViewLux plate reader (Perkin Elmer).  Raw data were uploaded into an institutional 
HTS database (Accelrys, San Ramon, CA) for further processing.  As a first calculation, T0 was 
subtracted from T90 for each individual well (“delta RFU”). Activity of each well was normalized 
on a per-plate basis using the following equation: 
 
Percent inhibition = (test_compound_delta RFU - negative_control_ delta 
RFU)/(positive_control_ delta RFU-negative_control_deltaRFU)*100 
 
Where “test_compound” is defined as wells containing test compound, “negative_control” is 
defined as the median of the wells containing test compounds, and “positive_control” is defined 
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as the median of the wells containing ZnCl2 or Z-Phe-Ala-diazomethylketone for rPfM18AAP or 
CTSL1, respectively (n = 24 wells). 
 
Each assay plate underwent a quality control check; a Z’ value greater than 0.5 was required for 
acceptance of data (11).  For titration experiments, triplicate percent inhibition values were plotted 
against compound concentration. A four-parameter equation describing a sigmoidal concentration-
response curve was then fitted with adjustable baseline using Assay Explorer software (Accelrys). 
Concentration-response curves and IC50 values presented in this manuscript were generated by 
Prism (GraphPad Software, San Diego, CA). 
 
Malaria cell lysate assay. This assay utilized soluble freeze-thaw extracts of parasites and the 
substrate H-Glu-NHMec as previously published. Briefly, in vitro infected human red blood cells 
were harvested, washed with PBS and parasites were then released using saponin. The released 
parasites were subjected to three rounds of freeze-thaw and extracts were harvested as supernatants 
(8). Activity of test compounds versus PfM18AAP extracts was assessed by incubating the 
compounds with the extracts in the presence of CoCl2 and H-Asp NHMec. Vehicle and background 
controls were included in the assay. Test compounds that inhibited extract activity decreased 
cleavage of the substrate, which was measured as a decrease in fluorescence proportional to the 
inhibitory activity of the test compound.  
Parasite growth assay. The whole-cell malaria growth assay was used to identify compounds that 
inhibit P. falciparum growth in red blood cells, i.e. P. falciparum’s asexual erythrocytic stage as 
previously published 98. Briefly, compounds were incubated with P. falciparum infected red blood 
cells (RBC) in hypoxanthine-free media. 3H-hypoxanthine was added to treated cultures. After 48 
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hours 3H incorporation was determined.  Vehicle and background (RBC) controls (DMSO ≤ 1%) 
were included on each plate. As designed, compounds that inhibit the growth of P. falciparum in 
RBC decreased the level of 3H incorporated.  
Ki determination and mode of inhibition. CID 6852389 and CID 23724194 powder samples were 
subjected to Ki determination versus purified recombinant PfM18AAP. Reaction buffer consisted 
of 50 mM Tris-HCl pH 7.5 + 0.1 mM CoCl2.  Reactions were run a 100 µL assay volume for 1 
hour with 60 second measurement intervals. The substrate Glu-NHMec was tested in a the range 
of 0.5 µM, 1 µM, 10 µM, 100 µM, 250 µM, and 500 µM while the inhibitor concentrations were 
tested 1 µM, 5 µM, 10 µM, and 50 µM. Enzyme and inhibitors were incubated 30 minutes with 
reaction buffer before substrate addition.  GraphPad Prism software was used for graphical 
(Lineweaver-Burk) and quantitative (non-linear regression) determination of inhibition mode and 
Ki.  
Cheminformatics: A Maximum Common Substructure hierarchical clustering (ChemAxon 
LibraryMCS 5.10.1) was used to identify the scaffolds of active compound families from the 125 
active compounds found from the PfM18AAP HTS (13-16).  In addition to clustering analysis, 
physical properties of the clustered compounds were calculated (ChemAxon Instant JChem 5.9.4). 
Calculated results included molecular mass, topological polar surface area, chiral atoms, H-bond 
acceptors/donors, ring count, and rotatable bonds. 
 
RESULTS 
Implementation of the rPfM18AAP & CTSL1 screening assays. To help identify potent and 
selective inhibitors we implemented a screening strategy that uses a counterscreen to triage non-
selective hits and assay artifacts at each HTS stage; in this case, recombinant CTSL1, a cysteine 
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peptidase derived from parasitic helminth F. hepatica, was selected as the counterscreen for 
rPfM18AAP compound hits. The rPfM18AAP & CTSL1 screening assays were both designed to 
measure the inhibition of recombinant enzyme by monitoring the fluorescence of a 
methylcoumarin-labeled peptide substrate (H-Glu-NHMec and Z-Leu-Arg-NHMec, respectively). 
The measured fluorescence signal increases as enzyme cleaves the substrate and releases 
aminomethylcoumarin, whereas enzymatic inhibitors leave the substrate intact, resulting in low 
amounts of measured fluorescence. The assay principle is illustrated for the rPfM18AAP screening 
assay in Figure 1; the CTSL1 counterscreen assay was similarly formatted with an appropriate 
fluorogenic substrate (Z-Leu-Arg-NHMec). As shown in Figure 2A the positive control inhibitor 
for the rPfM18AAP assay, Zn(II), yielded an IC50 of 662nM ± 314nM (N=33 plates). 
Concentration-response analysis of the CTSL1 inhibitor, Z-Phe-Ala diazomethylketone, resulted 
in an average IC50= 15.45 nM ± 2.66 nM (N=22 plates). 
The rPfM18AAP primary assay and CTSL1 counterscreen assay were implemented at a final 
volume of 5 µL/well in 1,536-well plates. The assays were screened against the entire available 
MLSMR collection; 277,728 unique compounds were tested in both assays.  All MLSMR 
compounds were screened at 7 µM for rPfM18AAP and 6uM for CTSL1.  For the rPfM18AAP 
screening assay, an IC100 of Zn(II) was used as a positive control for enzyme inhibition. The 
median of the wells containing test compounds were used as negative controls (i.e. IC0).  Using 
these controls (Figure 3), the rPfM18AAP assay demonstrated robust screening statistics. It had 
an average signal-to-background ratio (S/B) of 3.42 ± 0.89 and a Z’ of 0.84 ± 0.04 (n= 241 plates). 
The CTSL1 assay was similarly robust; using Z-Phe-Ala diazomethylketone and the median of the 
wells containing test compounds as positive and negative controls, respectively, yielded a S/B of 
3.61 ± 0.26 and a Z’ of 0.88 ± 0.04 over 247 plates.  
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Selection of hits. The excellent screening statistics dictated our ability to select active compounds 
from singlicate data (11). Due to an update in the MLSMR collection between the two screening 
campaigns, rPfM18AAP was tested against 291,944 compounds and CTSL1 was tested against 
302,759 compounds; this resulted in 277,728 compounds being tested in both assays.  For these 
compounds, the CTSL1 assay results were used as a counterscreen for the rPfM18AAP screening 
assay. That is, any compound found active against rPfM18AAP but not active in the CTSL1 assay 
was prioritized for follow-up in the next round of testing (Table 1). A graphical representation of 
these selection criteria is shown in Figure 4. As graphed in the correlation plot, compounds that 
are to the right of the rPfM18AAP inhibition cutoff (vertical dashed line) were considered active 
compounds in the rPfM18AAP screen (“hits”); hits that fall below the CTSL1 inhibition cutoff 
(horizontal dashed line) were considered selective inhibitors of rPfM18AAP. 
In order to further enrich the data set for downstream follow-up studies, fresh aliquots of 2,378 hit 
compounds demonstrating selective inhibition of rPfM18AAP were tested in triplicate against both 
assays. To confirm activity and selectivity, the primary HTS hit activity cutoffs were reapplied to 
each set of screening results. This yielded 125 compounds that confirmed selective activity against 
rPfM18AAP, i.e. their measured %inhibition was above the rPfM18AAP primary HTS activity 
cutoff and less than the CTSL1 counterscreen HTS activity cutoff.  Fresh aliquots of these 
compounds were obtained for further characterization in titration (IC50) assays. All compounds 
yielded IC50 values of <10µM in the rPfM18AAP titration assays; none of these demonstrated 
potency (defined as IC50 <10µM) against CTSL1.  
Cheminformatics results: Maximum Common Substructure clustering of the 125 compounds 
analyzed resulted in 30 cluster groups being identified. However, 21 of these clusters had 3 or less 
members, in which 15 were singletons.  In contrast, the four largest clusters (clusters: 1, 3, 6, 9) 
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encompassed ~53% of the 125 compounds evaluated. As shown in Figure 5, these four clusters 
contain catechol, triazole and benzamide moieties, which are found in compounds with known 
pharmacology (17-20).  The largest grouping of compounds was in cluster #9, containing 33 
compounds (~26%) with a methylated catechol moiety.  This cluster of compounds has 
distinguishing properties that include a moderate level of hydrophobicity (ALogP ~2.2) as well as 
greater enrichment in H-bond acceptors/donors number with respect to the other clusters.  Cluster 
#3 is the second largest grouping with 14 compounds represented by a 1,2,4 triazol-4-yl urea 
scaffold. These compounds have distinguishing properties that include greater hydrophilicity 
(ALogP ~0.36), smaller mass and a lack of chiral centers.  Cluster #6 is the third largest grouping 
with 10 compounds represented by a 1, 2, 4 triazol-4-yl acetamide scaffold, similar to cluster-3 in 
its structural and physical properties. Cluster #1 is the fourth largest grouping with 9 benzamides.   
The physical properties generally straddle the values found within the other three clusters. A 
summary of physical parameters for each cluster is presented in Figure 5. Clustering results and 
calculated physical properties for all compounds are shown in Supplemental Table #2 as well as 
Supplemental Table #3. 
Mechanistic assay results. From the 125 compounds that demonstrated potent and selective 
inhibition of rPfM18AAP, a subset of compounds most tractable for SAR studies were purchased 
or resynthesized as powder samples. These powder samples were retested to confirm inhibition of 
purified recombinant PfM18AAP, as well as in malaria lysates, and also tested for their ability to 
inhibit P. falciparum parasite growth via 3H hypoxanthine incorporation. Two efficacious 
compounds were identified from this effort: CID 6852389, (S)-(+)-Apomorphine hydrochloride 
hydrate, and CID 23724194, the hydrochloride salt of 4-[2-(acridin-9-ylamino)ethyl]benzene-1,2-
diol. CID 6852389 was found active in the P. falciparum lysate assay (84% efficacy at ≤5µM; CID 
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23724194 was unavailable for testing).  In the 3H hypoxanthine incorporation assay, CID 6852389 
and CID 23724194 yielded 87% inhibition and 96% inhibition at 10 µM test concentrations, 
respectively.  
All compounds that inhibited parasite growth by >50% were titrated and retested as concentration 
response curves in the same experiment. CID 6852389 and CID 23724194 had the highest potency 
in these assays, with IC50 values of 4µM and 1.3µM, respectively. CID 6852389 and CID 
23724194 were also assayed enzymatically to assess their mode of inhibition. Results of non-linear 
regression analysis for Ki values were 3.39 ± 0.36µM for CID 6852389 and 1.35 ± 0.15 µM for 
CID 23724194. Mode of inhibition was determined by software-based comparison of fits method 
using competitive, non-competitive, uncompetitive and mixed models of inhibition. The preferred 
fit was the non-competitive model of inhibition in all cases. Additionally, the mode of inhibition 
was confirmed by steady state velocity plots, semilog scale plots, as well as Lineweaver-Burke 
plots. As determined by these methods, both behave as non-competitive inhibitors of rPfM18AAP 
(Supplemental figure 1).  
 
Results from previous primary screening assays were used to better understand possible off-target 
activities and liabilities of CID 6852389 and CID 23724194. When tested in similarly formatted 
enzymatic inhibition assays run at Scripps Research Institute Molecular Screening Center 
(SRIMSC), these compounds were devoid of activity (cf. PubChem AIDs 1859, 1931, 651959). 
Similarly, where tested, they were also inactive in mammalian cytotoxicity (cf. PubChem AIDs 
1486, 1825) and bacterial viability (cf. PubChem AIDs 449731, 651606) screens, as well >100 
other primary screens run at the screening center. Remarkably both compounds were found to be 
inactive in all cell-based screens tested at the SRIMSC, except for two serotonin receptor screens 
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(cf. PubChem AIDs 612 and 504916). In summary, in silico evaluation of the activity of CID 
6852389 and CID 23724194 in a variety of cell based and biochemical primary screening assays, 
including screens that used heterologous target enzymes and similar detection methodologies to 
the rPfM18AAP primary assay, indicated that the activity of these two compounds was specific to 
rPfM18AAP.   
 
DISCUSSION 
Described here is our effort to identify small-molecule inhibitors of rPfM18AAP via an HTS 
approach. As formatted, both the rPfM18AAP primary screen and the CTSL1 counterscreen were 
highly amenable to automated screening in 1,536 well microtiter plates, with a throughput of 
~20,000 compounds tested per hour.  As indicated by Z’ and positive control IC50 values, excellent 
assay windows and consistent pharmacology were demonstrated throughout the HTS effort, which 
enabled facile identification of selective rPfM18AAP inhibitors. This screening approach 
identified 125 hit compounds with potent, selective inhibition of rPfM18AAP. Two of these 
compounds, CID 6852389 and CID 23724194, were found to be non-competitive inhibitors of 
PfM18AAP, with low-uM Ki values. 
As described previously (21-24), we applied a “parallel” screening approach for the rPfM18AAP 
HTS, where the CTSL1 counterscreen was used to triage hits at each stage of the rPfM18AAP 
campaign (Table 1). This was implemented since both the rPfM18AAP and CTSL1 assays shared 
similar assay protocols, including the use of the same coumarin-based fluorophore for 
measurement of activity. CTSL1, a cysteine metalloproteinase, would be expected to be affected 
by divalent metal ions such as zinc, or chelators of such. Divalent metal ions were not added as 
part of the reaction mix during the counterscreen assay so identifying chelators is less likely but, 
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similar in principle to rPfM18AAP, compounds that may coordinate metal atoms would be 
expected to affect the activity of CTSL1 and may be identified via this counterscreen.  To prioritize 
viable rPfM18AAP inhibitors, we triaged compounds that were active in both assays with the 
assumption that they optically interfered with the measurement of fluorescence in microtiter plates, 
or were promiscuous inhibitors. The validity of this assumption is partially supported by the results 
of our in silico analysis of  CID 6852389 and CID 23724194; not only were these compounds 
inactive in the CTSL1 counterscreen, but also in all other similarly formatted coumarin-based 
enzymatic assays run in our screening laboratory.   
 
At the stage of potency assays, recapitulating this parallel approach enabled facile identification 
of selective rPfM18AAP inhibitors in the HTS datasets, allowing us to prioritize compounds for 
labor-intensive mechanistic assays. Following the HTS stage, i.e. step 4 in table 1, 125 compounds 
remained that appeared to be selective inhibitors. At this stage a chemical triage was applied and 
76 compounds were procured for testing in the lysate and parasite growth assay. Not all compounds 
were available in sufficient quantity for testing in both assays in which case preference for usage 
was given to the parasite growth assay.  Compounds that were active in lysate assay, if tested and 
parasite growth assay were progressed for Ic50 determination in the parasite growth assay. Of 
those five compounds, 6852389 and CID 23724194 were found to be the most potent.   
 
Although the CTSL1 results were used to identify selective inhibitors for the rPfM18AAP HTS 
effort, it is important to note several MLSMR compounds also selectively inhibited CTSL1 (see 
Figure 4). Alternatively, it is reasonable to assume that our criteria for prioritizing viable leads in 
the HTS effort may have triaged genuine rPfM18AAP inhibitors.  For this reason, all results for 
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the rPfM18AAP and CTSL1 screening assays have been placed in a publically available database, 
PubChem (https://pubchem.ncbi.nlm.nih.gov/), which enables the re-examination and 
identification of compounds with apparent activity in either target’s screening assay.   
 
Cheminformatic analysis of the 125 hit compounds provides insight on the possible pharmacology 
of the hits identified from the HTS effort. As represented by the Cluster #9, catechols and 
catecholamines are well known stimulants (17).   Derivatives of a 1, 2, 4 triazol-4-yl urea, found 
in cluster #3, have been shown to possess anti-inflammatory and antibacterial activities (18). 
Cluster #6 and its 1,2,4 triazole derivatives have been associated with a wider range of 
pharmacology including anti-inflammatory, antibacterial, antifungal, anticancer,  analgesic and 
antidepressants (18,19).  Finally, cluster #1 and its benzamide scaffold have derivatives with 
antagonistic activities against various receptors such as dopamine D2, 5-HT2 and 5-HT3 receptors 
(20). Both CID 6852389 and CID 23724194 are nominally members of the “catechol” cluster #9. 
While catechols, in general, have been described as pan assay interference compounds (PAINS) 
(25), there is contradicting evidence that this is the case, here, such as lack of activity versus >100 
assays tested in our lab. Initial analysis of the catechols shown in Supplemental Table 3 
demonstrates a relatively flat SAR which really only obviates that the catechol is important for 
activity. Figure 5 also demonstrates most compounds from the 125 tested for Ic50 associate into 
cluster 9 so clearly the catechol component must be important for activity. In addition, the nearly 
identical activity of CID 2215 and CID 6852389 clearly demonstrate that similar structures have 
reproducible activity, yet stereo selectivity cannot be fully ascertained due to lack of informative 
compound registration. While these observations do not clarify whether the biological activity was 
simply due to, “interference”, in other words, the catechol compounds acting as PAINS or that the 
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catechol compounds might be coordinating the metal atoms that the enzyme requires to function, 
thus inhibiting the enzyme, we do know that rPfM18AAP reacts differently to various different 
metal ions. The enzyme is inhibited by zinc (> 1 mM) which, was employed as our positive control 
in our screening assays but, conversely is enhanced by cobalt and manganese. Therefore the 
relationship of metal ion binding is complex (26). While the catechol group can chelate metal ions 
and we believe this is important for their rPfM18AAP inhibitory activity, the compound structure 
is essential for specificity as the selected probes did not inhibit other malaria exo-metallo-
aminopeptidases such as PfM17LAP and PfM1AAP (Dalton, unpublished). Interestingly, another 
screening center has also reported that both CID 2215 and CID 6852389 inhibit a cell based 
luciferase reporter assay to identify inhibitors of P. falciparum growth in-vitro 
(http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=504834) with Ic50 values of similar 
potency. Still, taken together there are clearly some additional and important determinations to be 
made to better understand how the molecules described in this manuscript, in particular catechols, 
affect not only PfM18AAP but, also P. falciparum. Combined with other relevant biological data 
presented here, this provides a basis for future PfM18AAP probe development.  
 
The rPfM18AAP inhibitors detailed here, CID 6852389 and CID 23724194, yield potent, 
reproducible results across laboratories in both biochemical and whole-cell studies. In addition, 
these heterocyclic compounds contain a basic nitrogen atom, a physicochemical property that is 
suspected to encourage lysosomotropism (27).  They are the basis of continuing efforts to identify 
efficacious small molecule probes of rPfM18AAP, which will be the subject of future reports.  
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Table 1:  rPfM18AAP uHTS Campaign Summary and Results.  
 Screen type Target Number of 
compounds 
tested 
Selection criteria  Number of 
compounds 
selected 
PubChem 
AID 
Assay statistics 
Z’ S/B 
1 
1 
Primary 
Primary 
Counterscreen 
PfM18AAP 
CTSL1 
291,944 
302,759 
>28.03% inhibition 
>16.63% inhibition 
3,522 
1,481 
1822 
1906 
0.84 ± 0.04 
0.88 ± 0.04 
3.42 ± 0.89 
3.61 ± 0.26 
2 Confirmation PfM18AAP 
 
2,378 >28.03% inhibition 661 2170 0.87 ± 0.03 1.57 ± 0.04 
3 Counterscreen CTSL1 2,378 >16.63% inhibition 7 2178 0.79 ± 0.01 3.53 ± 0.20 
4 Titrations PfM18AAP 
 
125 IC50<10µM 125 
 
2195 0.88 ± 0.02 2.03 ± 0.05 
CTSL1 125 IC50<10µM 0 2196 0.84 ± 0.03 4.12 ± 0.04 
5 Powder testing PfM18AAP 
 
76 >50% inhibition 
 
22 492974 NA NA 
Malaria Cell Lysate 60 >50% inhibition 
 
28 492975 NA NA 
6 Follow-up Parasite Growth @ 
10µM 
76 >50% inhibition 
 
5 489015  NA NA 
Parasite Growth 
IC50 
 
5 IC50<5uM 2 489011 NA NA 
 *NA=Not 
Applicable 
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Figure 1: rPfM18AAP enzymatic assay principle. rPfM18AAP activity is determined by measuring the release of the 7-amino-
4-methylcoumarin fluorogenic group (NHMec) from a peptide substrate (H-Glu-NHMec). Represented by the wavy line, 
cleavage of H-Glu-NHMec’s glutamic acid group by rPfM18AAP liberates NHMec from the peptide, leading to increased well 
fluorescence. As designed the screening assay identifies compounds that inhibit rPfM18AAP-mediated cleavage, resulting in 
decreased well fluorescence.  
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Figure 2: Performance of positive controls in the rPfM18AAP and CTSL1 screening assays. (A) Zn(II) was used 
as the positive control for the rPfM18AAP screening assay. It yielded average IC50 = 662 ± 314nM for N=33 in the 
1,536 well plates. (B) Z-Phe-Ala-diazomethylketone (Z-Fa-Dk) was used as the positive control throughout the CTSL1 
HTS assay yielding an average IC50 = 15.45 ± 2.66nM for N=22. Note: Both curves were fitted using non linear 
regression analysis and the variable slope log (inhibitor) vs. response method provided by GraphPad Prism.  
A. B. 
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Figure 3: rPfM18AAP (left panel) and CTSL1 (right panel) primary HTS assay performance. Positive control wells 
are shown as inverted grey triangles (IC100  of ZnCl2  or Z-Phe-Ala-diazomethylketone). Results of compound wells 
(black triangles) and negative control wells (white squares) are also graphed. Calculated hit-cutoffs are indicated via 
dashed lines. Due to the high degree of compound activity found in the rPfM18AAP assay, data for both HTS campaigns 
was normalized to the median of the compound wells (IC0) and the median of the respective IC100. Hence, the noticeable 
shift below 0% inhibition for rPfM18AAP assay. 
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Figure 4: Comparison of rPfM18AAP and CTSL1 primary screening results. The results of 277,728 compounds (grey circles) 
are shown. The horizontal dashed line represents the CTSL1 activity cutoff while the vertical dashed line represents the rPfM18AAP 
activity cut-off. Green circles represent the two “hit” compounds that were identified as part of the primary HTS. Arrows indicate 
the screening results for CID 6852389 and CID 23724194. 
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Figure 5: Clustering results of potent rPfM18AAP hits. Presented are the most common substructure, and respective second tier derivatives 
for the four most populous clusters. Cluster #9 (33 compounds total) is represented by a 1,2 catechol moiety; Cluster #3 (14 total) is 
represented by a 1,2,4 triazol-4-yl-urea moiety; Cluster #6 (10 total) is represented by a (1,2,4 triazol-4-yl) acetamide moiety; and Cluster #1 
(9 total) is represented by a benzamide moiety. CID 6852389 and CID 23724194 both belong to Cluster #9. Cluster numbers are assigned by 
the clustering algorithm, all results are provided in the supplemental section. 
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Supplemental Figure 1: Determination of modes of inhibitor interaction using untransformed data analysis, semilog 
scale analysis and Lineweaver-Burk analysis of potent and selective inhibitors rPfM18APP.  Both compounds exhibit 
non-competitive inhibition.     
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 Step Amount of Volume 
or Time 
PfM18AAP HTS Assay Conditions CTSL1 Assay Conditions  
 Enzyme dispensing 2.5 µL/well Final concentration:  2.5 µg/mL of enzyme  in 50mM Tris 
pH 7.5, 0.05% BSA and 2mM CoCl2 
Final concentration: 0.75 µg/mL CTSL1 in 1mM Tris pH 
7.5, 0.1% BSA and 1mM DTT 
 
 
 
Compound addition 
 
Pre-incubation 
37 nL/well  
 
30 minutes 
Final concentration : 7 µM  
Final DMSO concentration: 0.7% 
Room temperature 
Final concentration : 6 µM  
Final DMSO concentration: 0.6% 
Room temperature 
 Substrate mix dispensing 2.5 µL/well Final concentrations: 50 µM H-Glu-AMC in 50mM Tris 
pH 8.8 
Final concentrations: 50 µM Z-Leu-Arg-MCA in 25 mM 
Tris HCl, pH 7.5, 1mM DTT 
 Incubation 90 minutes Room temperature Room temperature 
 Record Fluorescence Ex = 340nm, Em = 
450nm 
Read at T0 and T90 Read at T0 and T90 
 
Supplemental TABLE 1. 
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Supplemental Table 2: Shown are the average chemical properties for all compounds found within a given cluster grouping. 
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Identification of Anti-Malarial Inhibitors using Late Stage Gametocytes in a Phenotypic 
Live/Dead Assay 
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Abstract: 
Malaria remains a major cause of morbidity and mortality worldwide with ~3.3 billion people at 
risk of contracting malaria and an estimated 450 thousand deaths each year. While tools to reduce 
the infection prevalence to low levels are currently under development, additional efforts will be 
required to interrupt transmission.  Transmission between human host and vector by the malaria 
parasite involves gametogenesis in the host and uptake of gametocytes by the mosquito vector. 
This stage is a bottleneck for reproduction of the parasite making it a target for small-molecule 
drug discovery. Targeting this stage, we used whole P. falciparum gametocytes from in-vitro 
culture and implemented them into 1536 well plates to create a live-dead phenotypic anti-
gametocyte assay.  Using specialized equipment and upon further validation, we screened 
~150,000 compounds from the NIH repository currently housed at Scripps Florida. We identified 
100 primary screening hits which were tested for concentration response. Additional follow-up 
studies to determine specificity, potency and increased efficacy of the anti-gametocyte candidate 
compounds resulted in a starting point for initial medicinal chemistry intervention. From this, 13 
chemical analogs were subsequently tested as de-novo powders which confirmed original activity 
from the initial analysis and now provide a point of future engagement. 
 
Key words: Malaria, gametocyte, Plasmodium falciparum, parasite, 1536 well 
 
 
 
 
Introduction 
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According to the World Health Organization (WHO) the parasites responsible for causing human 
malaria, Plasmodium falciparum, P. vivax, P. ovale P. malariae and P. knowlsei infect up to 216 
million people per year resulting in an estimated 445,000 fatalities.77 Current antimalarial regimens 
are not fully effective due to emerging drug resistance and their inability to prevent 
transmission.17,78 Approximately 40% of the world’s population lives in areas where the risk of 
malaria transmission is high, typically the tropic zones located closer to the equator.27 
The WHO along with charitable organization such as Gates Foundation and the global ministries 
from highly affected countries, are now driving renewed efforts toward the eradication of malaria.  
While vector control strategies, including impregnated bed nets and drug therapies such as 
artemisinin combination therapies have helped tremendously their efficacy may have plateaued.  
Additionally, while at least one vaccine, Mosquirix or RTS,S exists, it appears to have limited 
efficacy in inducing either robust antigenic responses or long-lasting immunity, thus leaving some 
vaccinated individuals unprotected. It remains under study to determine just how effective it 
is.79,39,40  Vector control and case management by chemotherapy remain the primary means of 
control for malaria. In the best scenario, while we may be able to achieve low levels of infection, 
additional measures are still necessary for complete eradication. This is true, in part, because drug 
resistant parasite strains are evolving thus providing a reservoir for transmission.80  In other words, 
the route to complete elimination of malaria resides in our ability to not only block both the hepatic 
and erythrocytic stages of parasite replication within the human host but, also to block transmission 
or the parasite between the human host and the mosquito vector.   
Hence, we are focused on identifying inhibitors that act on this late-stage of the parasite’s lifecycle. 
Gametocytes are part of the sexual phase of the malaria parasite life cycle and are essential for 
transmission from one host to another via the mosquito. They are produced in the human host and 
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once mature remain in a state of arrested cell development until ingested by a feeding female 
Anopheles mosquito where they undergo further development (Figure 1A).33,34  P. falciparum 
gametocytes require 10-12 days to reach maturity, passing through five distinct stages (I-V) along 
the way (Figure 1B).31 As the gametocytes mature to stage V they become relatively metabolically 
inert until they are taken up by a feeding mosquito and they can remain in the host circulation for 
significant periods of time at subpatent levels. This lack of metabolic activity correlates to less 
druggable targets making them insensitive to almost all commonly used antimalarial agents and 
our own recent findings confirm and extend these results.81,12 However, some reports have found 
that late stage gametocytes have increased lipid requirements which is divergent from early stage 
asexual parasites making fatty acid metabolism a possible target.82 Still, we have confirmed that 
late-stage gametocytes (stage IV-V) are largely speaking refractory to treatment by all the classes 
of antimalarial agents tested. This data indicates that even clinically effective antimalarial 
treatment of the host may not lead to the prevention of transmission. The metabolite of 8-
aminoquinoline primaquine (PQ) is currently the only licensed antimalarial drug that is effective 
against late stage gametocytes.83 Unfortunately, there are side effects to treatment with PQ which 
decrease its usefulness. It is also known to cause acute hemolysis in patients with G6PD deficiency, 
for whom PQ is contraindicated. G6PD deficiency is highly prevalent in malaria endemic areas 
and severely limits the use of PQ. Early reports that Tafenoquine has activity against gametocytes 
have not been confirmed and it appears to have no in vitro activity against stage IV/V 
gametocytes.38 It too is contraindicated in patients with G6PD deficiency. Therefore, blocking 
transmission of malaria by targeting late-stage gametocytes remains a top priority.  
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Traditionally, HTS campaigns use one of two approaches to identify new agents against a given 
disease; cell based or target based. In contrast to the asexual stages, because late-stage gametocytes 
are essentially terminally differentiated, the effect of compounds on this stage cannot be monitored 
using cell multiplication as a marker. In addition, working with gametocytes is technically 
challenging and until very recently, methods for production of large numbers of gametocytes were 
not available.14,49 Consequently, we have little information with respect to the differences in 
protein expression and metabolism between late-stage gametocytes and asexually replicating 
parasites. As a result, neither a cell- or target-based HTS approach to identifying compounds with 
activity against gametocytes was feasible. However, as a result of improved gametocyte 
production methods and the development of tools for downstream analysis, by our group and 
others, large-scale anti-gametocidal HTS approaches are now feasible.84,85,86 
Herein, we describe the miniaturization and completion of a large-scale screening agenda using a 
phenotypic approach incorporating a live/dead assay which monitors ATP, and, hence, metabolic 
activity of gametocytes. Late-stage gametocytes were used in a rapid, cost effective, highly 
sensitive luminescent detection assay in 1536-well format for detection of phenotypic gametocyte 
inhibitors. We also report the results of a mammalian cell cytotoxicity assay which was employed 
as a counterscreen. 
Materials and Methods 
Assay reagents.  
BacTiter-Glo microbial cell viability assay detection reagents were purchased from Promega 
Corp., Madison Wisconsin, Part# G8231. Late-stage (Stage V) gametocytes were isolated and 
cryopreserved as previously described.14 These were subsequently shipped by overnight courier 
frozen on dry ice, to TSRI Florida where they were stored at -130 °C until the time of use. 
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Cryopreserved gametocytes were thawed and returned to culture via a dropwise saline solution 
revitalization procedure followed by resuspension at 62,500 gametocytes per milliliter in RPMI 
1640 (Life Technologies, 15750) supplemented with 10% human serum (BioWorld, 30611043-1), 
0.2% sodium bicarbonate and 10ug/ml of gentamycin (Life Technologies, 15750). Four µL of 
gametocyte cell suspension were then dispensed into each well of 1536-well microtiter plates (250 
cells per well) (Corning, part 7254) using the Flying Reagent Dispenser (FRD-Aurora Biosciences 
Corp). Next, 44 nL of test compound in DMSO, low control (DMSO alone, 1.08% final 
concentration) or high control (media only, no gametocytes) were added to the appropriate wells 
using the GNF pintool (GNF Systems). Low controls in this sense are “vehicle only” treated wells 
and will elicit an uninhibited luminescence response equivalent to the amount of viable 
gametocytes within the well whereas high control wells have no gametocytes and elicit no 
appreciable luminescence which is anticipated to be corollary to a compound with maximal 
inhibitory effect.  Plates were incubated for 24 hours at 37 °C, 95% relative humidity and 5% CO2, 
whereupon 4 µL of BacTiter-Glo solution was added to all wells. Plates were centrifuged at 1000 
RPM for 1 minute and luminescence was measured using a 30-second read on the ViewLux 
microplate reader (PerkinElmer Lifesciences). 
Compounds.   
The Molecular Libraries Small Molecule Repository library was provided by the NIH’s Molecular 
Libraries Initiative. Details regarding compound selection for this library can be found online 
(http://mli.nih.gov/mli/compound-repository/mlsmr-compounds/).  Briefly, the MLSMR library is 
a highly diversified collection of small molecules (more than 50% of compounds exhibit molecular 
weights between 350 and 410 g/mole) comprising both synthetic and natural products, from either 
commercial or academic sources, that can be grouped into the three following categories: specialty 
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sets of known bioactive compounds such as drugs and toxins, focused libraries aimed at specific 
target classes, and diversity sets covering a large area of chemical space. Solid samples (powders) 
were purchased by the University of Kansas Specialized Screening Center from various 
commercial sources. Purity of all final compounds was confirmed by RP HPLC/MS analysis and 
determined to be > 95%. 1H and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer 
(operating at 400 and 101 MHz, respectively) or a Bruker AVIII spectrometer (operating at 500 
and 126 MHz, respectively). NMR spectra for the 13 purchased compounds used in the structure-
activity relationship (SAR) analysis are shown in the supplemental materials. 
Data acquisition and analysis.  
All screening assays were run on a Kalypsys/GNF robotic platform in 1,536-well microtiter plates. 
Luminescence was measured by the ViewLux plate reader using a luminescence protocol that 
utilized a 30 seconds exposure time.  Raw data were uploaded into an institutional HTS database 
(Symyx Technologies, Santa Clara, CA) for further processing.  Activity of each well was 
normalized on a per-plate basis using the following equation: 
 
The percent inhibition of each test compound was calculated as follows: % 𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝐼𝐼 =  100 ∗ ( 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶− 𝑀𝑀𝑇𝑇𝐶𝐶𝑀𝑀𝑀𝑀𝐶𝐶 𝐿𝐿𝐶𝐶𝐿𝐿 𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝐶𝐶)( 𝑀𝑀𝑇𝑇𝐶𝐶𝑀𝑀𝑀𝑀𝐶𝐶 𝐻𝐻𝑀𝑀𝐻𝐻ℎ 𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝐶𝐶− 𝑀𝑀𝑇𝑇𝐶𝐶𝑀𝑀𝑀𝑀𝐶𝐶 𝐿𝐿𝐶𝐶𝐿𝐿 𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝐶𝐶𝐶𝐶𝐶𝐶)  
Where: 
Test Compound is defined as wells treated with test compound. Low Control is defined as wells 
treated with DMSO only. High Control is defined as wells treated with media only and no 
gametocytes. 
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Each assay plate underwent a quality control check; a Z’ value greater than 0.5 was required for 
acceptance of data.87  Any assay plate for which the Z’ value did not exceed 0.5 was rescheduled 
for another robotic procedure until an acceptable Z’ value was observed.  
A mathematical algorithm was used to determine nominally inhibiting compounds in the primary 
screen. Percent inhibition is calculated for each individual well including control wells using the 
expression included above and applied here to determine an interval-based cut-off which was 
applied to take into account assay noise and general variability within compound activity to help 
preserve and identify more hits at the primary HTS phase.88 Four values were calculated: (1) the 
average percent inhibition of all high controls tested plus three times the standard deviation of the 
high controls, (2) the average percent inhibition of all low controls tested minus three times the 
standard deviation of the low controls, (3) the average percent inhibition of all compounds tested 
between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, 
(3) and (4), was used as a cutoff parameter, i.e. any compound that exhibited greater % 
inhibition/activity than the cutoff parameter was declared active. 
For titration experiments, triplicate percent inhibition values were plotted against compound 
concentration. A four-parameter equation describing a sigmoidal concentration-response curve 
was then fitted with adjustable baseline using Assay Explorer software (Symyx). Concentration-
response curves and IC50 values presented in this manuscript were generated by Prism (GraphPad 
Software, San Diego, CA). In cases where the highest concentration tested did not result in greater 
than 50% inhibition, the IC50 was determined manually as greater than the highest concentration. 
Compounds with an IC50 greater than 10 µM were considered inactive. Compounds with an IC50 
equal to or less than 10 µM were considered active. 
Counterscreen 
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The purpose of this cell-based assay is to determine if compounds that originally were found to 
inhibit viability of late stage P. falciparum gametocyte in a primary HTS assay, also are cytotoxic 
to mammalian cells, an undesirable feature. In the past, counterscreening utilizing this method 
when screening for other parasite targets has been extremely helpful in ruling out non-specific 
cytotoxic compounds, and, hence we sought to apply the same principle here.15 
This assay employs Jurkat cells, a human T-cell line originally isolated from an adolescent male 
with T cell leukemia. The cells are grown in suspension which facilitates tissue culture and 
preparation for dispensing in the assay. The end-point assay presented here employed a similar 
reagent to the primary assay, CellTiter-Glo luminescent reagent (Promega Corp. Part G7573), 
which contains luciferase enzyme to catalyze the oxidation of beetle luciferin to oxyluciferin and 
light in the presence of ATP, in this case from Jurkat cells. Since metabolically active cells produce 
ATP, an increase in the number of dead or dying cells will correlate with a reduction in ATP levels. 
As designed, compounds that inhibit cell viability and reduce intracellular ATP will reduce the 
catalytic conversion of luciferin into oxyluciferin, resulting in decreased luciferase activity and 
well luminescence. This assay included doxorubicin as a positive control, an antibiotic used as an 
anti-cancer drug which elicits an appropriate anti-proliferative effect on Jurkat cells.99 Compounds 
are tested in triplicate using a 10-point 1:3 dilution series starting at a maximum nominal test 
concentration of 83.3 µM. 
Jurkat cells (clone E6.1; ATCC Cat# TIB-152) were routinely cultured in suspension in T-175 
standing flasks at 37 0C in 95% relative humidity (RH) at 5% CO2. Media consisted of RPMI-1640 
containing 10% dialyzed fetal bovine serum, 0.1 mM NEAA, 1mM Sodium Pyruvate, 25mM 
HEPES, 5mM L Glutamine, and 1x antibiotic. 
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Prior to the start of the assay, cells were suspended to a concentration of 100,000 cells/ml in media. 
To start the assay, 5 µL of media was dispensed into the first two columns of a 1536 well plate 
and 5 µL of cell suspension was dispensed to the remaining wells (500 cells per well). The assay 
was started immediately by dispensing 42 nL of test compound in DMSO, Doxorubicin (8 µM 
final concentration) or DMSO alone (0.6% final concentration) to the appropriate wells. The plates 
were then incubated for 48 hours at 37 0C, 5% CO2 and 95% RH). 
Following the two-day incubation, plates were equilibrated to room temperature for 10 minutes 
and 5 µL of CellTiter-Glo reagent was added to each well. Plates were centrifuged and incubated 
at room temperature for 10 minutes. Well luminescence was measured on the ViewLux plate 
reader. The percent inhibition for each compound was calculated exactly as it was for the primary 
HTS assay using the following controls: Test Compound is defined as wells containing test 
compound, Low Control is defined as wells containing DMSO only (0% inhibition), and High 
Control is defined as wells containing 8 µM doxorubicin (100% inhibition). 
Structure  
 
Results 
Since all HTS at Scripps is done in 1536-well format our former 96-well method was further 
miniaturized to optimize conditions based on Z’ value and reproducible response to methylene 
blue, a known inhibitor of malaria (Table 1).12,89 In particular, we optimized the number of 
gametocytes necessary per well to remain in the linear range of the detection modality, the 
incubation time, and further validated for HTS in the context of our fully automated screening 
system. This resulted in using 250 gametocytes per well at >90% viability, immediately adding 
test compound in 75:25 DMSO:H2O, and incubating for 24hrs prior to adding BacTiter-Glo 
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luminescence detection reagent. These conditions led to reproducible Z’ factor averaging 0.53±0.1 
over the course of 124 assay test plates.  After testing >153,000 compounds at ~11 µM, we 
identified 100 actives using a cut-off set at >38% inhibition (Figure 2). This effectively sets the hit 
cut-off such that it approaches the level of the sample field. Still, the hit rate was very low, 
observed as 0.1% of the compounds. This is further reflected by the average Z score assessed over 
the same course of plates equal to 0.60±0.05. Here Z factor is calculated using the method to 
generate Z’ but incorporates the use of the sample field in the expression used in place of the low 
controls. As such, achieving lower Z scores, such as those <0.5, would represent higher activity of 
the samples tested, which isn’t the case here.  
Considering the low number of actives identified, we proceeded immediately to the concentration-
response curve (CRC) determination phase, avoiding the expenditure of time and cost associated 
with the typical confirmation and counterscreen phase. Since this biological target is of major 
significance, difficult to hit, and the NIH repository allowed for up to 275 compounds to proceed 
to CRCs we expanded the hit list to include the top 275 molecules for testing. Of those, 244 were 
available and subsequently tested in both the primary assay and counterscreen assay for CRC 
determination. Of the 244 molecules, only two compounds were identified with moderate potency 
and selectivity (see Table 2). These two molecules, SR-01000751192 and SR-01000471307 were 
found to have potencies <10 µM in the whole gametocyte assay (Figure 3). Only SR-01000751192 
exhibited minimal cytotoxicity when tested in the Jurkat T-cell toxicity assay (>83 µM), an 
example of an HTS qualified assay for cytotoxicity profiling.15   
After validation of the hit compounds from dry powders that were originally identified from the 
high-throughput screening conditions and prior to moving into serious SAR optimization where 
analogs are typically obtained via laboratory synthesis, a routine procedure of analog-by-catalog 
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(ABC) is usually performed to streamline the process. In this step, structurally close analogs are 
purchased from different commercially available sources that provide a basic idea to map the 
structural changes and their correlate with inhibitory activities. Often, this process provides useful 
insights towards which directions the structural changes should be performed to improve the 
potency before the onset of SAR optimization using synthetic efforts. In this project, we carried 
out a quick ABC process by purchasing analogs that are close structural analogs of the hit 
compound SR-01000751192 with single-, double-, and triple-point changes (as summarized in the 
attached files). Note that SR-01000751192 provided batch-to-batch reproducibility as identified 
from samples from the solid physical state. A raw 4 parameter curve fit for this compound yield 
nearly identical IC50s (7.1µM -batch2 vs. 8 µM-original hit). A small set of analogs (13) were 
obtained as fresh samples from the solid physical state. The late-stage SAR assay performed well 
with Z’ values averaging better than 0.6, and the methylene blue control worked as expected. The 
counterscreen assay also behaved as expected, with consistent Z’ scores, and response to the 
control doxorubicin. Unfortunately, improved anti-gametocydial activity was not observed for any 
of the 13 compounds purchased for initial SAR, although the compound sample from the solid 
physical state for the original compound hit did recapitulate the activity observed previously (see 
supplemental Table 1). We therefore conclude that changing with pyridyl substituent at the 
position 3 of the pyrazole with phenyl, substituted phenyl, and cyclopropyl groups led to 
diminished activities. We also observed that changing the thiazolyl structure by adding 
substituents, or additional heteroatom wasn’t tolerated.  
Discussion 
This work represents the first report of a large-scale HTS campaign completed in 1536 well format 
against late-stage P. falciparum gametocytes. Most HTS efforts targeting P. falciparum are 
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directed at the liver and blood stages of the parasite life cycle (Figure 1). Some involve target based 
approaches such as isolation of purified proteins and screening for protease inhibitors that may 
block the active site for its respective substrate.8, 9 Others that have the potential to identify 
transmission blocking molecule are low throughput and or non-homogenous in assay format 
making them ill-suited for large scale HTS.86  As a critical biological target of unmet therapeutic 
need, we set the bar high in terms of accepting any compound hit of appreciable activity to proceed 
for further testing. This meant incorporating a conservative primary HTS cut-off followed by a 
rather relaxed 10 µM IC50 cut-off in the late-stage analysis. While our efforts were in progress, we 
overcame a few key hurdles. During the HTS of the gametocyte project there was an unavoidable 
but, significant batch-to-batch difference in the gametocyte numbers and viability which was 
overcome by pooling the batches at the point of HTS testing. This afforded us with acceptable Z’ 
scores. Methylene blue, while not a good anti-malarial drug due to side effects in humans, was 
used as a pintool-transferred control on each plate and was also tested for anti-gametocidal 
pharmacologic response as a CRC control during each experiment and during each run. It is notable 
that the Z and Z’ values are nearly overlapping, which simply indicates the overall activity of the 
test compound was very low. The initial hits, while low in efficacy, do consistently reproduce 
activity in both labs (Scripps and QIMR Berghofer Medical Research Institute (QIMRB). While it 
is unusual to obtain such a low hit rate against such a large number of diverse compounds tested, 
namely the Molecular Library Probe Production Centers Network (MLPCN) library which has 
yielded multiple clinical drugs,91 this observation highlights the complexity and natural resistance, 
or refractiveness, of the gametocytes to the cytotoxic effects of small molecules, similar to what 
has been observed by others to date. Incorporating a cytotoxicity counterscreen was effective in 
focusing our attention on SR-01000751192 and SR-01000599986, but with the limited hit set may 
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not be as useful at this stage as originally planned. Ultimately, we were successful in completing 
the HTS campaign against this difficult target and there were no insurmountable challenges 
encountered. 
This work involved a multi-institute and multi-content initiative that was supported by the 
MLPCN.  One of the mains goals of the MLPCN was to identify novel molecular probes; i.e. 
ligands that supersede the activity of all prior art in all assays of relevance to support such an 
achievement. So our goal was to obtain a series of small molecules that met these criteria. Based 
on this outcome, a probe was not identified for this project which would have been defined as a 
compound the elicited an anti-gametocidal effect < 500nM IC50 versus the primary assays and 
which produced reasonable potency in the low-throughput mechanism-of-action assays, such as 
the RBC infectivity assay performed at QIMRB.  
An alternative approach that has shown promise by others incorporated fragment based screening 
against biochemical targets in tandem with phenotypic assays.92,93 Perhaps, armed with a 
biochemical assay directly targeting gametocytes, this hybrid approach would have helped here 
but, to our knowledge none such exist that are HTS amenable. We conclude that this method of 
HTS provides a path forward for future HTS, perhaps testing larger more diverse libraries for anti-
gametocidal inhibitor identification and development. 
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Table 1. Stepwise Protocol for the 1536-Well Plate Live/Dead Gametocyte Assay  
 
Table 2: Summary of the Ultra-HTS campaign to Identify Inhibitors of Late Stage 
Plasmodium falciparum Gametocytes 
Step Screen Type Readout Target 
PubChem 
AID 
Number of 
Compounds 
Tested 
Selection 
Criteria 
Number of Selected 
Compounds (Hit 
Rate) Z' S/B 
1a Primary Luminescence Gametocytes 743093 153,343 38.12%a 100 (0.1%) 0.53±0.15 28±8 
Order Step Condition Comments 
1 
Thaw frozen stock 
Revitalization of 
late-stage 
gametocytes 
Dilute to 62,500 gametocytes per milliliter in RPMI 1640 supplemented with 
10% human serum, 0.2% sodium bicarbonate and 10ug/ml of gentamycin 
2 Dispense gametocytes 4μL/well 250 cells/well into 1536-well plates (Corning, part 7254) 
3 Pin compounds/controls 44nL Compounds pinned at ~10µM final concentration in ~1% DMSO 
4 Incubation 24 hours 37 °C, 95% relative humidity and 5% CO2 
5 Dispense BacTiter-Glo 4µl/well Luminescence substrate is stable at RT 
6 Incubation 10 minutes 
RT incubation allows for plates to equilibrate to alleviate temperature 
gradient prior to reading 
7 
Read Luminescence 
Plates were centrifuged and luminescence was measured on aViewLux 
microplate reader (PerkinElmer, Turku, Finland) using a luminscence 
protocol that utilized a 30 seconds exposure time 
 172 
2a Dose-response Luminescence Gametocytes 1117278 244 IC50 < 10µM 2 (1.0%) 0.80±0.02 48±1 
2b Dose-response Luminescence Jurkat T-Cells 1117277 244 IC50 < 10µM 5 (2.0%) 0.87±0.02 31±2 
3a MedChem Luminescence Gametocytes 1159507 13 Chemistb 0 (0%) 0.88±0.03 14±1 
aThe primary screen hit cutoff was calculated using the interval-based cutoff. 
bDue to the novelty of this target, compounds with any observable activity in the Concentration-
Response assay, and not in the counterscreen, were of interest for follow-up. 
 
Figure Legends: 
Figure 1: (A) Lifecycle of Plasmodium falciparum. Gametocytes are transmitted to the mosquito 
vector during a blood feed. The point in the lifecycle where transmission-blocking therapies may 
be effective is annotated with the large red X. (1B) the five stages of gametocyte development of 
which this HTS effort targets stages IV and V. 
Figure 2: (A) Scatterplot of the data from the primary HTS campaign. Wells were treated with 
either test compounds (black), no gametocytes (high control=red) or gametocytes only (low 
control=green). The hit cutoff is shown as a dashed line at 38% inhibition. Titration results of the 
known anti-gametocyte cytotoxic compound methylene blue, N=4 separate experiments, N=16 
wells per replicate point, error bars are shown. The average calculated IC50 was 14.7±6.6µM. 
Figure 3: Structure-activity relationship of the top active molecules identified as hits in this HTS 
campaign. Compounds are ranked with most potent first. Data has been normalized to “no 
gametocytes” as 100% inhibition vs. “DMSO and gametocytes” only. Data is plotted as log M on 
the x-axis versus percent inhibition on the Y-axis.
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Analytical Experiments for 13 analogs tested post HTS for the Gametocidal Project 
 
General Experimental Section 
 
Purity of all final compounds was confirmed by HPLC/MS analysis and determined to be > 90%. 
1H and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400 and 
101 MHz respectively) or a Bruker AVIII spectrometer (operating at 500 and 126 MHz 
respectively) in CDCl3 (residual internal standard CHCl3 = δ 7.26), DMSO-d6 (residual internal 
standard CD3SOCD2H = δ 2.50), or acetone-d6 (residual internal standard CD3COCD2H = δ 2.05). 
The chemical shifts (δ) reported are given in parts per million (ppm) and the coupling constants 
(J) are in Hertz (Hz). The spin multiplicities are reported as s = singlet, bs = broad singlet, bm = 
broad multiplet = doublet, t = triplet, q = quartet, p = pentuplet, dd = doublet of doublet, ddd = 
doublet of doublet of doublet, dt = doublet of triplet, td = triplet of doublet, tt = triplet of triplet, 
and m = multiplet. 
 
HPLC/MS analysis was carried out with gradient elution (5% CH3CN to 100% CH3CN) on an 
Agilent 1200 RRLC with a photodiode array UV detector and an Agilent 6224 TOF mass 
spectrometer (also used to produce high resolution mass spectra).  Automated preparative RP 
HPLC purification was carried out by Mass Directed Fractionation with gradient elution (a narrow 
CH3CN gradient was chosen based on the retention time of the target from LCMS analysis of the 
crude sample) on an Agilent 1200 instrument with photodiode array detector, an Agilent 6120 
quadrupole mass spectrometer, and a HTPAL LEAP autosampler. Fractions were triggered using 
an MS and UV threshold determined by HPLC/MS analysis of the crude sample. One of two 
column/mobile phase conditions were chosen for both analysis and purification to promote the 
targets neutral state: 0.02% formic acid with Waters Atlantis T3 5um, 19 x 150mm (Prep scale), 
Waters Atlantis T3 1.7um, 2.1 x 50mm (Analytical Scale); pH 9.8 NH4OH with Waters XBridge 
C18 5um, 19 x 150mm (Prep scale), Waters BEH C-18 1.7um, 2.1 x 50mm (Analytical Scale).  
 
All the following compound analogs were commercially available. Compound purity was 
measured on the basis of peak integration (area under the curve) from UV/vis absorbance (at 214 
nm), and compound identity was determined on the basis of high resolution mass analysis and 1H  
NMR spectroscopy. 
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KSC-439-001  
1-phenyl-N-(thiazol-2-yl)-3-(p-tolyl)-1H-pyrazole-4-carboxamide: Physical state: white solid; 
Purity: 99%; 1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H), 9.29 (s, 1H), 7.93–7.84 (m, 2H), 
7.74–7.67 (m, 2H), 7.64–7.55 (m, 2H), 7.54 (d, J = 3.6 Hz, 1H), 7.46–7.37 (m, 1H), 7.31–7.17 (m, 
3H), 2.37 (s, 3H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C20H17N4OS 361.1118; Found 
361.1111. 
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KSC-439-001.1.fid in DMSO at 400.23 MHz
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.34 (s, 1H), 9.29 (s, 1H), 7.93 – 7.84
(m, 2H), 7.74 – 7.67 (m, 2H), 7.64 – 7.55 (m, 2H), 7.54 (d, J  = 3.6 Hz, 1H),
7.46 – 7.37 (m, 1H), 7.31 – 7.17 (m, 3H), 2.37 (s, 3H).
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KSC-439-002  
1-phenyl-3-(pyridin-3-yl)-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide: 
 
 
 Physical state: white solid; Purity: 100%; 1H NMR (400 MHz, DMSO-d6) δ 12.43 (s, 1H), 9.42 
(s, 1H), 8.98 (dd, J = 2.3, 0.9 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 8.21 (dt, J = 7.9, 1.9 Hz, 
1H), 7.96–7.75 (m, 2H), 7.69–7.57 (m, 2H), 7.55 (d, J = 3.5 Hz, 1H), 7.52 (ddd, J = 7.9, 4.8, 0.9 
Hz, 1H), 7.49–7.37 (m, 1H), 7.27 (d, J = 3.6 Hz, 1H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C18H14N5OS 348.0914; Found 348.0910. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.43 (s, 1H), 9.42 (s, 1H),
8.98 (dd, J  = 2.3, 0.9 Hz, 1H), 8.63 (dd, J  = 4.8, 1.7 Hz, 1H),
8.21 (dt, J  = 7.9, 1.9 Hz, 1H), 7.96 – 7.75 (m, 2H), 7.69 – 7.57
(m, 2H), 7.55 (d, J  = 3.5 Hz, 1H), 7.52 (ddd, J  = 7.9, 4.8, 0.9 Hz,
1H), 7.49 – 7.37 (m, 1H), 7.27 (d, J  = 3.6 Hz, 1H).
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KSC-439-003  
3-cyclopropyl-1-phenyl-N-(thiazol-2-yl)-1H-pyrazole-5-carboxamide: Physical state: white 
solid; Purity: 100%; 1H NMR (400 MHz, DMSO-d6) δ 12.11 (s, 1H), 7.84–7.71 (m, 2H), 7.65–
7.56 (m, 2H), 7.55–7.47 (m, 2H), 7.27 (d, J = 3.5 Hz, 1H), 6.82 (d, J = 0.7 Hz, 1H), 1.95–1.74 (m, 
1H), 1.07–0.93 (m, 2H), 0.86–0.72 (m, 2H); HRMS (ESI-TOF) m/z: [M + H]+  Calcd for 
C16H15N4OS 311.0961; Found 311.0956. 
 
 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.5
KSC-439-003.1.fid in DMSO at 400.23 MHz
2.
01
2.
15
1.
03
1.
00
0.
95
2.
00
2.
02
2.
05
1.
00
0.
79
22
0.
80
31
0.
80
48
0.
80
89
0.
81
57
0.
81
85
0.
82
15
0.
83
14
0.
97
82
0.
98
80
0.
99
39
0.
99
89
1.
00
48
1.
00
88
1.
01
47
1.
02
57
1.
02
81
1.
87
94
1.
88
12
1.
88
74
1.
88
91
1.
90
02
1.
90
20
1.
91
28
1.
91
46
1.
92
10
2.
49
10
 D
M
S
O
2.
49
56
 D
M
S
O
2.
50
03
 D
M
S
O
2.
50
49
 D
M
S
O
2.
50
95
 D
M
S
O
3.
33
10
 H
D
O
6.
82
02
6.
82
19
7.
26
50
7.
27
38
7.
49
13
7.
50
45
7.
50
93
7.
51
08
7.
51
47
7.
52
51
7.
52
92
7.
53
80
7.
57
94
7.
58
07
7.
58
22
7.
58
47
7.
59
40
7.
59
70
7.
60
04
7.
60
21
7.
60
41
7.
60
68
7.
61
41
7.
61
87
7.
62
09
7.
76
47
7.
77
11
7.
77
37
7.
77
66
7.
77
85
7.
78
68
7.
79
16
7.
79
52
7.
79
84
12
.1
11
1
N
N
O
NH
S
N
1
H NMR (400 MHz, DMSO- d
6
) δ  12.11 (s, 1H), 7.84 – 7.71 (m, 2H),
7.65 – 7.56 (m, 2H), 7.55 – 7.47 (m, 2H), 7.27 (d, J  = 3.5 Hz, 1H),
6.82 (d, J  = 0.7 Hz, 1H), 1.95 – 1.74 (m, 1H), 1.07 – 0.93 (m, 2H),
0.86 – 0.72 (m, 2H).
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KSC-439-004  
3-(4-fluorophenyl)-1-phenyl-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide: Physical state: 
white solid; Purity: 98%; 1H NMR (400 MHz, DMSO-d6) δ 12.38 (s, 1H), 9.34 (s, 1H), 8.01–7.75 
(m, 4H), 7.67–7.55 (m, 2H), 7.54 (d, J = 3.6 Hz, 1H), 7.50–7.38 (m, 1H), 7.36–7.25 (m, 2H), 7.26 
(d, J = 3.6 Hz, 1H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H14FN4OS 365.0867; Found 
365.0865. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.38 (s, 1H), 9.34 (s, 1H), 8.01
– 7.75 (m, 4H), 7.67 – 7.55 (m, 2H), 7.54 (d, J  = 3.6 Hz, 1H), 7.50 –
7.38 (m, 1H), 7.36 – 7.25 (m, 2H), 7.26 (d, J  = 3.6 Hz, 1H).
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KSC-439-005  
 
3-(4-chlorophenyl)-1-phenyl-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide: Physical state: 
white solid; Purity: 100%; 1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 9.35 (s, 1H), 7.94–
7.85 (m, 2H), 7.90–7.83 (m, 2H), 7.65–7.55 (m, 2H), 7.58–7.49 (m, 3H), 7.48–7.38 (m, 1H), 7.26 
(d, J = 3.6 Hz, 1H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H14ClN4OS 381.0571; 
381.0569. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.40 (s, 1H), 9.35 (s,
1H), 7.94 – 7.85 (m, 2H), 7.90 – 7.83 (m, 2H), 7.65 – 7.55
(m, 2H), 7.58 – 7.49 (m, 3H), 7.48 – 7.38 (m, 1H), 7.26 (d,
J  = 3.6 Hz, 1H).
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KSC-439-006  
3-(4-methoxyphenyl)-1-phenyl-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide: Physical state: 
white solid; Purity: 93%; 1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H), 9.31 (s, 1H), 7.95–7.87 
(m, 2H), 7.85–7.73 (m, 2H), 7.65–7.55 (m, 2H), 7.55 (d, J = 3.5 Hz, 1H), 7.48–7.37 (m, 1H), 7.27 
(d, J = 3.6 Hz, 1H), 7.08–6.96 (m, 2H), 3.83 (s, 3H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C20H17N4O2S 377.1067; Found 377.1071. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.34 (s, 1H), 9.31 (s, 1H), 7.95 – 7.87
(m, 2H), 7.85 – 7.73 (m, 2H), 7.65 – 7.55 (m, 2H), 7.55 (d, J  = 3.5 Hz, 1H),
7.48 – 7.37 (m, 1H), 7.27 (d, J  = 3.6 Hz, 1H), 7.08 – 6.96 (m, 2H), 3.83 (s,
3H).
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KSC-439-007  
1,3-diphenyl-N-(thiazol-2-yl)-1H-pyrazole-5-carboxamide: Physical state: white solid; Purity: 
96%; 1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H), 7.56 (d, J = 3.6 Hz, 1H), 7.50–7.43 (m, 3H), 
7.43–7.34 (m, 5H), 7.33 (s, 1H), 7.31–7.23 (m, 3H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for 
C19H15N4OS 347.0961; Found 347.0962. 
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KSC-439-007.1.fid in DMSO at 400.23 MHz
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.34 (s, 1H), 7.56 (d, J  =
3.6 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.43 – 7.34 (m, 5H), 7.33 (s,
1H), 7.31 – 7.23 (m, 3H).
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KSC-439-008  
1-phenyl-3-(pyridin-4-yl)-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide: Physical state: white 
solid; Purity: 98%; 1H NMR (400 MHz, DMSO-d6) δ 12.48 (s, 1H), 9.39 (s, 1H), 8.83–8.48 (m, 
2H), 7.95–7.88 (m, 2H), 7.87–7.75 (m, 2H), 7.66–7.56 (m, 2H), 7.56 (d, J = 3.5 Hz, 1H), 7.50–
7.38 (m, 1H), 7.28 (d, J = 3.6 Hz, 1H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H14N5OS 
348.0914; Found 348.0913. 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.513.0
KSC-439-008.1.fid in DMSO at 400.23 MHz
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.48 (s, 1H), 9.39 (s, 1H), 8.83
– 8.48 (m, 2H), 7.95 – 7.88 (m, 2H), 7.87 – 7.75 (m, 2H), 7.66 –
7.56 (m, 2H), 7.56 (d, J  = 3.5 Hz, 1H), 7.50 – 7.38 (m, 1H), 7.28
(d, J  = 3.6 Hz, 1H).
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KSC-439-009  
N-(4,5-dihydrothiazol-2-yl)-1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxamide: Physical 
state: white solid; Purity: 95%; 1H NMR (400 MHz, DMSO-d6) δ 8.98 (dd, J = 2.3, 0.9 Hz, 1H), 
8.92 (s, 1H), 8.60 (dd, J = 4.8, 1.7 Hz, 1H), 8.23 (dt, J = 8.0, 1.9 Hz, 1H), 7.96–7.85 (m, 2H), 7.58–
7.52 (m, 2H), 7.48 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.43–7.37 (m, 1H), 3.63 (t, J = 7.9 Hz, 2H), 
3.22 (t, J = 7.9 Hz, 2H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H16N5OS 350.1070; Found 
350.1075. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  8.98 (dd, J  = 2.3, 0.9 Hz, 1H),
8.92 (s, 1H), 8.60 (dd, J  = 4.8, 1.7 Hz, 1H), 8.23 (dt, J  = 8.0, 1.9 Hz,
1H), 7.96 – 7.85 (m, 2H), 7.58 – 7.52 (m, 2H), 7.48 (ddd, J  = 7.9,
4.8, 0.9 Hz, 1H), 7.43 – 7.37 (m, 1H), 3.63 (t, J  = 7.9 Hz, 2H), 3.22
(t, J  = 7.9 Hz, 2H).
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KSC-439-010  
1-phenyl-N-(thiazol-2-yl)-3-(m-tolyl)-1H-pyrazole-4-carboxamide: Physical state: white solid; 
Purity: 96%; 1H NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H), 9.30 (s, 1H), 7.96–7.85 (m, 2H), 
7.65–7.57 (m, 4H), 7.55 (d, J = 3.6 Hz, 1H), 7.46–7.40 (m, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.28–
7.20 (m, 2H), 2.38 (s, 3H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C20H17N4OS 361.1118; 
Found 361.1123. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.36 (s, 1H), 9.30 (s, 1H), 7.96 – 7.85
(m, 2H), 7.65 – 7.57 (m, 4H), 7.55 (d, J  = 3.6 Hz, 1H), 7.46 – 7.40 (m, 1H),
7.36 (t, J  = 7.6 Hz, 1H), 7.28 – 7.20 (m, 2H), 2.38 (s, 3H).
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KSC-439-011  
N-(4,5-dihydrothiazol-2-yl)-1,3-diphenyl-1H-pyrazole-5-carboxamide: Physical state: white 
solid; Purity: 98%; 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 7.47 – 7.40 (m, 3H), 7.38 – 
7.33 (m, 3H), 7.33 – 7.28 (m, 2H), 7.27 – 7.20 (m, 2H), 7.02 (s, 1H), 3.65 (t, J = 7.9 Hz, 2H); 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H17N4OS 349.1118; Found 349.1121. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  9.80 (s,
1H), 7.47 – 7.40 (m, 3H), 7.38 – 7.33 (m,
3H), 7.33 – 7.28 (m, 2H), 7.27 – 7.20 (m,
2H), 7.02 (s, 1H), 3.65 (t, J  = 7.9 Hz, 2H).
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KSC-439-012  
N-(5-methylthiazol-2-yl)-1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxamide: Physical 
state: white solid; Purity: 96%; 1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 9.38 (s, 1H), 8.97 
(dd, J = 2.2, 0.9 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 8.19 (ddd, J = 7.9, 2.2, 1.7 Hz, 1H), 7.94–
7.76 (m, 2H), 7.65–7.55 (m, 2H), 7.51 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.49–7.38 (m, 1H), 7.28–
7.11 (m, 1H), 2.36 (d, J = 1.3 Hz, 3H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C19H16N5OS 
362.1070; Found 362.1074. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  12.24 (s, 1H), 9.38 (s,
1H), 8.97 (dd, J  = 2.2, 0.9 Hz, 1H), 8.63 (dd, J  = 4.8, 1.7 Hz,
1H), 8.19 (ddd, J  = 7.9, 2.2, 1.7 Hz, 1H), 7.94 – 7.76 (m,
2H), 7.65 – 7.55 (m, 2H), 7.51 (ddd, J  = 7.9, 4.9, 0.9 Hz,
1H), 7.49 – 7.38 (m, 1H), 7.28 – 7.11 (m, 1H), 2.36 (d, J  =
1.3 Hz, 3H).
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KSC-439-013  
1,3-diphenyl-N-(1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxamide: Physical state: white 
solid; Purity: 96%; 1H NMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 7.51–7.44 (m, 3H), 7.43–7.38 
(m, 5H), 7.33 (s, 1H), 7.31–7.26 (m, 2H); HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C18H14N5OS 
348.0914; Found 348.0919. 
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1
H NMR (400 MHz, DMSO- d
6
) δ  9.19 (s,
1H), 7.51 – 7.44 (m, 3H), 7.43 – 7.38 (m,
5H), 7.33 (s, 1H), 7.31 – 7.26 (m, 2H).
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